

**David Allen Mrazek, M.D., F.R.C. Psych.**

Chair of Department of Psychiatry and Psychology  
Director of the SC Johnson Genomics of Addictions Program  
Mayo Clinic

**Office Address:** Department of Psychiatry and Psychology  
Mayo Clinic  
200 First Street, SW  
Rochester, Minnesota 55905  
Phone: 507-284-8891  
Fax: 507-266-3319  
Email: mrazek.david@mayo.edu

**Citizenship:** U.S.A.

**Date and Place of Birth:** October 1, 1947; Fort Riley, Kansas

**Marital Status:** Married: Patricia J. Mrazek, Ph.D.

**Children:** Nicola (B.D. 8/22/79)  
Matthew (B.D. 11/27/81)  
Michael (B.D. 5/4/84)  
Alissa (B.D. 4/11/88)

**Education:**

1965-1969 B.A. Cornell University, Ithaca, New York; cum laude

1969-1973 M.D. Wake Forest University School of Medicine  
Winston Salem, North Carolina

1972 Externships in Psychiatry at Stanford University, Palo Alto, California  
and in Neurology at the National Hospital at Queens Square, London

1973-1975 Resident in General Psychiatry, Cincinnati General Hospital

1975-1977 Fellow in Child Psychiatry, University of Colorado Medical Center

1977 Chief Child Psychiatry Fellow, University of Colorado Medical Center

**Academic Appointments:**

- 1977-1979 Lecturer in Child Psychiatry, Institute of Psychiatry, London
- 1979-1984 Assistant Professor of Psychiatry, University of Colorado School of Medicine
- 1984-1990 Associate Professor of Psychiatry and Pediatrics  
University of Colorado School of Medicine
- 1990-1991 Professor of Psychiatry, Behavioral Sciences, and Pediatrics  
University of Colorado School of Medicine
- 1991-2000 Professor of Psychiatry, Behavioral Sciences, and Pediatrics  
The George Washington University School of Medicine
- 1998-2000 Leon Yochelson Professor of Psychiatry  
George Washington University School of Medicine
- 2000- Professor of Psychiatry and Pediatrics  
College of Medicine, Mayo Clinic

**Clinical Appointments:**

- 1977-1979 Honorary Senior Registrar  
Maudsley Hospital, London, England  
1977-1978 Family Therapy Unit with Christopher Dare  
1978-1979 Children's Unit with Sir Michael Rutter
- 1979-1991 Director, Division of Pediatric Psychiatry  
National Jewish Center for Immunology and Respiratory Medicine
- 1991-1998 Chair of Department of Psychiatry and Behavioral Sciences  
Children's National Medical Center
- 1996-2000 Chair of Department of Psychiatry and Behavioral Sciences  
The George Washington University School of Medicine
- 2000- Chair of Department of Psychiatry and Psychology, Mayo Clinic

**Licensure:**

- 1973 Federal Licensing Examination (FLEX)
- 1973 Medical License, State of North Carolina (18687)
- 1974 Medical License, State of Ohio (36974)
- 1974 Diplomate, National Boards, Parts I, II, and III (ID No. 147968)
- 1976 Medical License, State of Colorado (19866)
- 1991 Medical License, District of Columbia (19167)
- 1991 Medical License, State of Virginia (0101047327)
- 1993 Medical License, State of Maryland (D44432)
- 2000 Medical License, State of Minnesota (43217)
- 2001 Medical License, State of Arizona (31070)
- 2004 Medical License, State of Florida (ME0091781)

### **Board Certification and Service:**

- 1978 Diplomate of Psychiatry, American Board of Psychiatry and Neurology (19525)
- 1978 Membership in the Royal College of Psychiatry (M.R.C. Psych.)
- 1980 Diplomate of Child Psychiatry, American Board of Psychiatry and Neurology (1342)
- 1981-1982- Examiner in Psychiatry for the American Board of Psychiatry and Neurology
- 1982- Examiner in Child Psychiatry for the American Board of Psychiatry and Neurology
- 1992 Elected to Fellowship in the Royal College of Psychiatry (F.R.C. Psych.)
- 1992-1998 Child and Adolescent Psychiatry Written Examination Committee of the American Board of Psychiatry and Neurology
- 2000 Informatics Committee of the American Board of Psychiatry and Neurology
- 2003- Director of American Board of Psychiatry and Neurology
- 2005-2007 Chair, Child and Adolescent Psychiatry Steering Committee of the American Board of Psychiatry and Neurology
- 2008- Member, Executive Committee, American Board of Psychiatry and Neurology

### **Honors, Special Recognition, and Awards:**

- 1974 First Prize Maurice Levine Essay Award, University of Cincinnati
- 1975 Second Prize Maurice Levine Essay Award, University of Cincinnati
- 1983 Research Scientist Development Award Level I N.I.M.H.
- 1986 Visiting Professor, Royal Children's Hospital, Melbourne, Australia
- 1986 Visiting Professor, The Hospital for Sick Children at Great Ormond Street, London, England
- 1986 First listed in *International Who's Who in Medicine*
- 1987 First listed in *Who's Who in the West*
- 1988 Research Scientist Development Award Level II N.I.M.H.
- 1988 First listed in *Who's Who Emerging Leaders in America*
- 1990 First listed in *Who's Who in America*
- 1991 Roerig Visiting Professor, University of California at Davis
- 1992 41st Ruth Gray Memorial Lecture, Evanston Hospital
- 1992 Distinguished Visiting Professor, University of Pittsburgh/W.P.I.
- 1993 Elected to Fellowship in the Royal College of Psychiatrists
- 1993 Invited to present the Laufer Memorial Lecture, Brown University
- 1994 First listed in *The Best Doctors in America*
- 1994 Elected to Membership in The American College of Psychiatrists
- 1995 Visiting Professor, University of Hawaii
- 1995 First listed in *Who's Who in the World*
- 1996 Blanche F. Ittleson Award for Outstanding Research in Child Psychiatry awarded by the American Psychiatric Association
- 1997 Visiting Professor, McGill University and Hospital St Justine, Montreal
- 1998 Appointed as the Leon Yochelson Professor of Psychiatry at George Washington University
- 1999 Agnes Purcell McGavin Award for Outstanding Research in Prevention awarded by the American Psychiatric Association
- 1999 Elected to Membership in the Cosmos Club, Washington, D.C.
- 1999 Visiting Professor, The Cleveland Clinic
- 2000 Elected to Membership in the Benjamin Rush Society
- 2000 Irving Philips Memorial Award for Outstanding Research in Prevention awarded by the American Academy of Children and Adolescent Psychiatry

- 2001 First listed in *Who's Who in the Midwest*
- 2002 First listed in *Who's Who in Medicine and Healthcare*
- 2003 Master Clinician, American Academy of Child and Adolescent Psychiatry, New Orleans
- 2003 Elected to Fellowship in the American College of Psychiatrists
- 2004 Master Clinician, American Academy of Child & Adolescent Psychiatry
- 2004 David Bean Visiting Distinguished Professor, University of South Dakota
- 2005 10<sup>th</sup> Annual Gene L. Usdin, M.D., Distinguished Visiting Lecturer, Oschner Clinic
- 2005 Master Clinician, American Academy of Child and Adolescent Psychiatry, Toronto
- 2005 Creativity in Psychiatric Education Award – American College of Psychiatry
- 2005 Simon Wile Award – American Academy of Child and Adolescent Psychiatry, Toronto
- 2006 Honorary Professorship, Universidad Nacional de San Agustin in Arequipa, Peru.
- 2006 Honorary Professorship, Universidad Peruana Cayetano Heredia, Peru.
- 2007 Listed in *Guide to America's Top Psychiatrists*, Consumers' Research Council of America.
- 2008 Agnes Purcell McGavin Award for Distinguished Career Achievement in Child and Adolescent Psychiatry, American Psychiatric Association. Awarded by the American Psychiatric Association Annual Meeting.

**Professional Society Memberships:**

- American Academy of Child and Adolescent Psychiatry (Fellow)
- American Psychiatric Association (Distinguished Fellow)
- Royal Society of Medicine (Fellow)
- Royal College of Psychiatrists (U.K.) (Fellow)
- American College of Psychiatrists (Fellow)
- Association of Chairmen of Psychiatry at Children's Hospitals (Founding President)
- International College of Psychosomatic Medicine (Fellow)
- Society for Research in Child Development (Fellow)
- American Psychological Society (Fellow)
- Benjamin Rush Society
- American Medical Association
- Research Society on Alcoholism
- Association for Child and Adolescent Mental Health (U.K.)
- Society of Professors of Child and Adolescent Psychiatry (Secretary-Treasurer, 2000-2002)
- American Society for Human Genetics
- American Psychosomatic Society
- Academy for Eating Disorders

**Selected National Committees:**

- 1981-1986 Program Committee, American Academy of Child Psychiatry
- 1985-1986 Committee on the Editorship and Stewardship  
Journal of the American Academy of Child and Adolescent Psychiatry
- 1987-1994 Committee on Chronic Illness, American Academy of Child and Adolescent Psychiatry
- 1988-1989 Work Group on Scientific Issues in Child Psychiatry  
American Academy of Child and Adolescent Psychiatry
- 1989- Child Psychiatry Committee, Group for the Advancement of Psychiatry  
(Co-Chair 1994-2000)
- 1989-1992 Committee on Disorders of Infancy and Early Childhood DSM IV.
- 1989-1994 Work Group on Research, American Academy of Child and Adolescent Psychiatry

1991-1995 Interdisciplinary Committee, The Society for Research in Child Development (Chair 1993-1994)

1992-1998 Chair, Committee on Research, The Society for Professors of Child and Adolescent Psychiatry

1994-1997 Committee on Research Training, American Psychiatric Association

1994-1997 Committee on Prevention, American Academy of Child and Adolescent Psychiatry

1996-1999 Elected to Council of the American Academy of Child and Adolescent Psychiatry

1997-1998 Council, American Academy of Child and Adolescent Psychiatry

1997-1998 Chairman, Committee on Quality Assurance and Improvement Committee – American Psychiatric Association

1997-1998 Member of the Council on Economic Affairs, American Psychiatric Association

1997-2001 Chairman, Committee on Healthcare Reform and Financing, American Academy of Child and Adolescent Psychiatry

2001- Behavioral Health Measurement Advisory Panel, National Committee on Quality Assurance

2001 Member of the Agnes Purcell McGavin Award Selection Corresponding Committee, American Psychiatric Association

2003- Member of ACGME Residency Review Committee in Psychiatry

2003- Member of ACGME Database Committee

2003-2006 Member of the APA/Lilly Products Resident Research Award Corresponding Committee, American Psychiatric Association

2003-2007 Member of American Board of Medical Specialties, Database and Information Technology Advisory Committee

2004- Steering Committee on Work Force Issues, American Academy of Child and Adolescent Psychiatry

2004- Member of the Board of Directors, The National Foundation for Mental Health

2004 Member, Committee on Research and Development–Psychiatry, American Board of Psychiatry and Psychology

2005-2006 Chair, Child and Adolescent Psychiatry Steering Committee, American Board of Psychiatry and Psychology

2006- Council on Children, Adolescents and Their Families, American Psychiatric Association (Chair 2006-2008)

2007-2008 Vice-Chair of the ACGME Residency Review Committee in Psychiatry

## **Selected University and Hospital Committees:**

### **University of Colorado**

- 1981-1986 Executive Committee, Colorado Child and Adolescent Psychiatric Society  
1984-1991 Executive Committee, Division of Child Psychiatry, Department of Psychiatry, University of Colorado School of Medicine  
1985-1991 Promotion and Tenure Committee, Department of Psychiatry, University of Colorado School of Medicine  
1988-1991 Institutional Review Board, National Jewish Center for Immunology and Respiratory Medicine

### **George Washington University/Children's National Medical Center**

- 1991- 2000 Executive Committee, Department of Psychiatry and Behavioral Sciences, The George Washington University  
1991- 2000 Appointment, Promotion, and Tenure Committee, Department of Psychiatry and Behavioral Sciences, The George Washington University School of Medicine,  
1991-1995 Quality Assurance/Risk Management Committee, Children's National Medical Center  
1991-1998 Executive Committee, Department of Psychiatry, Children's National Medical Center  
1992-1998 Council of Center Directors, Children's Research Institute  
1992-1998 Research Advisory Committee, Children's National Medical Center  
1994-1998 Appointment, Promotion and Tenure Committee, Department of Pediatrics, George Washington University School of Medicine  
1995 Chair, Search Committee for Chief Medical Officer, Children's National Medical Center  
1996-2000 Committee of the Chairs, George Washington University School of Medicine  
1996-2000 Faculty Senate, George Washington University School of Medicine  
1996-2000 Executive Committee of the Medical Staff of University Hospital, George Washington University School of Medicine  
1996-1998 Financial Services Committee of Medical Faculty Associates, George Washington University School of Medicine  
1997-1998 Executive Committee of the Faculty Senate, George Washington University School of Medicine  
1999-2000 Incorporation Committee of Medical Faculty Associates, George Washington University School of Medicine  
1999-2000 Elected to Vice-Chairmanship of the Committee of the Chairs, George Washington University School of Medicine  
2000 Elected to Chairmanship of the Committee of the Chairs, George Washington University School of Medicine

## Mayo Clinic

2000-	The Committee of Department Chairs
2000-	Executive Committee, Department of Psychiatry and Psychology
2000-	Genomic Education Steering Committee
2001-	Library Advisory Subcommittee
2003-2004	Practice Optimization and Expense Management Group
2004	Chair, Search Committee for Institutional Bioethicist
2005-	Mayo Clinical Pharmacology Training Committee
2007-2009	Member, Internal Advisory Committee, Mayo Clinic Center for Clinical and Translational Research
2008	Center for Individualized Medicine Forum

## Selected Reviews and Referee Work:

Editorial reviews for:

	American Journal of Medical Genetics: Neuropsychiatric Genetics
	American Journal of Psychiatry
	American Journal of the Diseases of Children
	Archives of General Psychiatry
	Annals of Allergy
	Biological Psychiatry
	Brain, Behavior, and Immunity
	Chest
	Child Abuse and Neglect: The International Journal
	Contemporary Psychology
	CNS Spectrum
	Journal of the American Academy of Child and Adolescent Psychiatry
	Journal of Child Psychology and Psychiatry
	Journal of Interpersonal Violence
	Journal of Pediatric Psychology
	Journal of Traumatic Stress
	Pediatrics
	Pharmacogenomics Journal
	Psychosomatic Medicine
	Psychosomatics
1980-1984	Criminal and Violent Behavior Review Committee, NIMH
1983-1988	Editorial Board, American Academy of Child Psychiatry Journal
1985	Reviewer for the American Psychiatric Association Achievement Reward
1987	Scientific Reviewer for the Burroughs Wellcome Foundation
1987-1992	Consulting Editor, Infant Mental Health Journal
1988	Scientific Reviewer for the W.T. Grant Foundation
1989-1993	Scientific National Advisor to the Preventive Intervention Research Center, Albert Einstein University
1989	American Psychiatric Association Consultant, APA Task Force on Psychiatric Treatment
1989-1991	MacArthur Foundation Network Grant Review Committee
1989-1992	Life Course and Prevention Research Review Committee, NIMH
1990-1992	National Advisor, National Child Health Assessment Project
1991	Reviewer for Panel on "Infants and Toddlers at Risk", Society for Research in Child Development

### **Selected Reviews and Referee Work (cont'd.):**

1991	Chairman, Special Review Committee, NIMH
1991-1993	Chairman, Research Proposal Review Committee, The Academy of Child and Adolescent Psychiatry/NIMH Physician Scientist Development Program
1992-1995	Ad Hoc Reviewer for NIMH
1992-1993	Child and Adolescent Risk and Prevention Research Review Committee, NIMH
1993-1994	Panel Chairman, Society for Research in Child Development
1994-	Contributing Editor, Annals of Allergy
1996	Section Editor of the Human Development Section in <i>Psychiatry</i> , edited by Tasman, Kay, and Lieberman
1996-1999	Reviewer and Site Visitor of clinical training program for the Residency Review Committee (R.R.C.)
1996	Program Reviewer for the Annual Meeting, Society for Research in Child Development
1996	Consultant, Cambridge Hospital, Boston, Massachusetts
1996-1998	Reviewer, American Psychiatric Association Young Investigators Awards
1997	Consultant, Cleveland Clinic, Cleveland, Ohio
1999	Consultant Department of Psychiatry, University of Illinois, Chicago, Illinois
1999	Ad Hoc Review, NIMH Biobehavioral and Biobehavioral Processes IRG, Center for Scientific Review, NIH
2002-	Editorial Board, Current Opinions in Pediatrics
2002	Section Editor of Human Development Section in <i>Psychiatry</i> , (2 <sup>nd</sup> Edition), edited by Tasman, Kay, and Lieberman
2003-2008	Member, Accreditation Council for Graduate Education, Residency Review Committee for Psychiatry
2005-	Editorial Advisory Board Member, Current Pediatric Reviews
2006	Section Editor of Human development Section in <i>Psychiatry</i> , (3 <sup>rd</sup> Edition), edited by Tasman, Kay and Lieberman

## **Research Support:**

1. Awarded support for research into "Clinical Strategies for the Evaluation of the Affective Components of Early Child Development", by the Grant Foundation, 1977. (Declined when appointed to lectureship in child psychiatry at the Institute of Psychiatry, London, with salary support to do the above project).
2. Awarded support for "Regulation of Emotion in Severely Asthmatic Young Children", by the Developmental Psychobiology Endowment Fund, January 1, 1982 to June 30, 1983 (\$6,000).
3. Awarded Research Scientist Development Award Level I for "Regulation of Emotion in Young Chronically Ill Children", by the National Institute of Mental Health, July 1, 1983, to June 30, 1988 (\$268,678).
4. Awarded support for "Childhood Asthma: The Interplay of Psychological, Psychiatric, and Physiological Factors" by The W. T. Grant Foundation, April 1, 1985 to March 31, 1988 (\$261,625).
5. Awarded support for "Etiology of Physical and Mental Health Problems during the Transition Period: A Twin Study" (with Dr. David Fulker) by the MacArthur Foundation, June 1, 1985 to May 31, 1986 (\$19,933).
6. Awarded support for "Asthma Risk Project: Viral Culture Protocol" by the Clinical Research Center, Department of Pediatrics, University of Colorado Health Sciences Center, July 1, 1985- June 30, 1986 (\$15,000).
7. Awarded support for "Assessment of Psychological and Physiological Stresses in Children at High Genetic Risk for the Development of Asthma" by The W. T. Grant Foundation, March 1, 1987 to March 31, 1988 (\$56,358).
8. Awarded support for preservation of sera samples for prospective Asthma Risk Project, January, 1988, by the Developmental Psychobiology Endowment Fund, University of Colorado (\$4,000).
9. Awarded continued support for "Assessment of Psychological and Physiological Stresses in Children at High Genetic Risk for the Development of Asthma" by The W. T. Grant Foundation, April 1, 1988 to March 31, 1991 (\$289,576).
10. Awarded support for "Early Interventions to Prevent or Delay Asthma" by the Hasbro Children's Foundation, July 1, 1988 to June 30, 1990 (\$287,103).
11. Awarded support for "Defining Early Psychopathology in Three Year Olds" by the MacArthur Foundation, July 15, 1988 to April 30, 1989 (\$6,970).
12. Awarded Research Scientist Development Award Level II for "Stress, Viral, and Immune Factors in Early Illness" by the National Institute of Mental Health, September 30, 1988 to September 29, 1993 (\$264,600).
13. Awarded support for "Temperament and Atopic Illness" by the MacArthur Foundation, July 1, 1989 to June 30, 1990 (\$5,970).

14. Awarded support for "Reconceptualization of a Psychiatric Assessment for Three Year Olds" by the MacArthur Foundation, May 1, 1990 to April 30, 1991 (\$7,000).
15. Awarded support for the "Asthma Intervention Project" by the Hasbro Children's Foundation, February 1, 1991 to January 31, 1993 (\$100,000).
16. Awarded continuing support for "Assessment of Psychological and Physiological Stressors in Children at Genetic Risk for the Development of Asthma" by the W. T. Grant Foundation, April 1, 1991 to March 31, 1994 (\$293,361).
17. Awarded support for "Assessment of Early Psychopathology in Preschool Children" by the MacArthur Foundation, May 1, 1991 to April 30, 1992 (\$47,600).
18. Awarded support for "National Institute of Mental Health/American Academy of Child and Adolescent Psychiatry Institutional Training Award" by the National Institute of Mental Health, September 30, 1991 to September 29, 1996 (\$3,141,358).
19. Awarded support for "Research Training in Early Developmental Psychopathology" by the National Institute of Mental Health, September 30, 1994 to June 30, 1999 (\$405,780).
20. Awarded support for "Assessment of Psychological and Physiological Stressors in Children at Genetic Risk for the Development of Asthma" by The William T. Grant Foundation, October 1, 1994 to September 30, 1995 (\$125,353).
21. Awarded contract for "Development and Validation of Individual-Based Methods for Mental Health Research" by the National Institute of Mental Health, October 1, 1994 to September 30, 1997 (\$25,000).
22. Awarded support for "Research Training in Early Developmental Psychopathology" by the National Institute of Mental Health, July, 1999 to June 30, 2004 (\$975,241).
23. Awarded support for "Treatment of Disruptive Disorders Associated with the Onset of Bipolar Disorder" by Abbott Laboratories, August 1, 1999 to June 30, 2001 (\$310,000).
24. Awarded support for "Pharmacogenomic Studies of Antidepressants" by Mayo Foundation, September 1, 2000, to December 31, 2003 (\$300,000).
25. Awarded support for "Genomic Study of Mood Disorders" by Cooper Family Foundation, May 1, 2003, through April 30, 2006 (\$1,500,000).
26. Awarded support for "Genomics of Addictions" by S.C. Johnson Foundation, January 1, 2004, through December 31, 2009 (\$19,400,000).
27. Awarded support for "Pharmacokinetics and Pharmacodynamics of SSRI's" by the National Institute of General Medical Sciences, July 12, 2005 through June 30, 2010 (Principal Investigator, \$1,965,187) as part of the NIGMS "Pharmacogenomics of Phase II Drug Metabolizing Enzymes" (Richard Weinsilboum, Principal Investigator, \$12,604,747).
28. Awarded support for "Phase I AmpliChip Project" by Roche Diagnostics, July 1, 2005 through December 31, 2006 (\$158,539).

29. Awarded support for “The creation of an interactive web-based clinical decision making tool entitled the “Pharmacogenomic Algorithm for Psychotropic Pharmacotherapeutic Applications” (David Mrazek, principal investigator)
30. Awarded support for “Pharmacogenomic Screening for Selection of Psychotropic Medication” Discovery translation Grant (David Mrazek, principal investigator) September, 2006 through August, 2008 (\$480,736).

### **Selected Other Professional Activities:**

- 1979-1984 Coordinator of Clinical Pediatric Services for Young Children (0 to 5 years), National Jewish Hospital, Denver, Colorado
- 1981-1988 Research collaboration with Dr. Arthur Robinson, "Longitudinal study of children with genetic abnormalities", Denver, Colorado
- 1983 Dissertation Committee, Dr. Geri Wolfson, University of Denver, "Psychological considerations of pediatric asthma death"
- 1984-1985 President, Colorado Child and Adolescent Psychiatric Society
- 1984-1991 Faculty Member, NIMH Postdoctoral Research Training Program in Developmental Psychobiology, University of Colorado
- 1985 Member, the MacArthur Foundation "Transitions in Early Development" Research Network
- 1985-1986 Co-Chair, The Fourth Biennial Developmental Psychobiology Research Group Retreat, Estes Park, Colorado
- 1986-1988 Chair, The Fifth Biennial Developmental Psychobiology Research Group Retreat, Estes Park, Colorado
- 1989 Participant, The Jackson Laboratory/Johns Hopkins Course in Medical and Experimental Mammalian Genetics, Bar Harbor, Maine
- 1990 Invited participant, The MacArthur Foundation Executive Committee Review of Psychiatric Assessment of Preschool Children, London, England
- 1991-2000 Faculty, Annual Pediatric Board Review Course, Washington, D.C.
- 1991 Invited participant Institute for Mental Health Initiatives Program, "Fostering Resilience," Washington, D.C.
- 1991-1996 Program Director, AACAP/NIMH Physician Scientist Development Award Program
- 1992 Participant, Chief of Service Short Course, Harvard Business School and School of Public Health, Boston, Massachusetts
- 1992 Invited Participant, Institute of Medicine Committee Examining the Cost of Services for the Severely Mentally Ill
- 1992-1998 Center Director, Neuroscience Center, Children's Research Institute, Children's National Medical Center
- 1993 Invited Participant and Task Group Chair, National Institute of Health Working Conference on Behavioral Medicine
- 1996 Participation in task force examining implications of managed care for academic psychiatry [June in Boston, September in San Francisco]
- 1997 Elected Founding President of the Association of Chairs of Psychiatry in Children's Hospitals (ACOPACH)
- 1998 Participant, Advanced Chief of Service Short Course, Harvard Business School and School of Public Health, Boston, Massachusetts
- 1999 Participant, The Jackson Laboratory/Johns Hopkins Course in Medical and Experimental Mammalian Genetics, Bar Harbor, Maine
- 2001-2009 Course Director, Mayo Clinic Annual Psychiatric Genomics Course
- 2003-2009 Course Director, APA Course on Psychiatric Genomics
- 2007-2009 Course Director, Mayo Clinic Annual Psychiatric Pharmacogenomics Course
- 2008 Course Director, Mayo Clinic Biological Frontiers of Alcohol Addiction Course

## **Major Administrative and Scientific Interests:**

My primary clinical interest has been the prevention and early treatment of heritable illnesses that have their onset in childhood. I originally studied risk and protective factors associated with prevention of the onset of asthma. Subsequently, I have focused on the evaluation and treatment of juvenile onset bipolar disorder. This included the development of early screening protocols designed to identify children at risk for early illnesses who would be most likely to benefit from selective and targeted preventive interventions. Since coming to the Mayo Clinic, I have made a major commitment to investigating pharmacogenomic characteristics of psychotropic medications. In 2004, I initiated a major effort to better understand the genomic basis of addictions.

My research interests originally evolved within the context of understanding the emotional development of young children with a special focus on the prevention of the onset of physical and emotional disorders. Initially I studied populations of infants and preschool children who were at risk for abnormal emotional development. These studies included young children who had been physically abused or whose parents had received atypical early parenting. Subsequently, I focused my studies on examining the early emotional development of physically ill children and particularly the impact of severe life threatening asthma on the development of children with asthma and their families.

A major research effort has been the design and implementation of a prospective longitudinal study examining the relative contributions of ten etiological factors to the onset of asthma in a group of genetically at risk children. This study represents the first major research effort designed to define the effect of stress on susceptibility to asthma or allergic illness in genetically vulnerable infants. This longitudinal study has continued for the past twenty years and is currently being conducted by Dr. Mary Klinnert who is still at The National Jewish Medical and Research Center. We subsequently initiated a large intervention project with 140 families. The objective was to prevent or delay asthma and allergy in a group of genetically at risk children. This study compared the relative effects of an educational intervention, dietary counseling, and a psychologically oriented home intervention and was the first randomized controlled trial of these contrasting interventions in this at risk population.

My research interests have broadened to include the study of a variety of genetically mediated illnesses with a specific focus on the examination of the effects of environmental influences on gene expression. At the George Washington University, we explored these interactions by conducting a double blind randomized controlled placebo trial of valproic acid to treat the prodromal symptoms of bipolar disorder in children at genetic risk.

On coming to the Mayo Clinic in September 2000, my primary goal has been to link the clinical service system with the highly developed capacity to systematically establish genotypic variability available at the Clinic. In 2002, we began work on the development of pharmacogenomic screening of patients taking psychotropic medications using new microarrays designed to assess genotypic variability resulting in atypical metabolism of antidepressant medications. In 2003, we received funding to further develop our implementation of microarrays for diagnostic applications as well as the initiation of MRS spectroscopy studies of child and adult patients with bipolar disorder. Based on this work, we have filed a patent describing a genotypically informed methodology for the selection and dosing of antidepressant medication. Most recently, we have launched a major new effort to genotypically characterize vulnerabilities in patients, including children and adolescents, with problems in the use of substances with a specific focus on the development of genotypically informed treatments for alcoholism.

## **Bibliography for David A. Mrazek, M.D., F.R.C. Psych.**

### **A. Articles in Peer-Reviewed Journals**

1. **Mrazek DA** (1974), Integration or segregation of theoretical frameworks: A challenge in psychiatric education. *Comprehensive Psychiatry*, 17:249-257 (First Prize Maurice Levine Essay).
2. Gaensbauer TJ, **Mrazek DA**, Emde RN (1979), Patterning of emotional response in a playroom laboratory situation. *Infant Behavior and Development*, 2:163-178.
3. **Mrazek DA**, Prugh D (1980), Critical incidents in child psychiatric training. *Journal of the American Academy of Child Psychiatry*, 19:311-319.
4. **Mrazek DA** (1980), The child psychiatric examination of the sexually abused child. *Child Abuse and Neglect*, 4:275-284. [also republished in *Sexually Abused Children and their Families*, eds. P.B. Mrazek and C.H. Kempe. New York: Pergamon Press, pp. 143-153.]
5. Gaensbauer TJ **Mrazek DA** (1981), Differences in the patterning of affective expression in infants. *Journal of the American Academy of Child Psychiatry*, 20:673-691.
6. **Mrazek DA**, Dowdney L, Rutter ML, Quinton D (1982), Mother and preschool child interaction: A sequential approach. *Journal of the American Academy of Child Psychiatry*, 21:453-464.
7. **Mrazek DA** (1983), Long term follow up of an adolescent perpetrator of sexual abuse. *Child Abuse and Neglect*, 7:239-240.
8. Garralda ME, Weiselberg M, **Mrazek DA** (1983), A survey of training in child and adolescent psychiatry. *British Journal of Psychiatry*, 143:498-504.
9. Dowdney L, **Mrazek DA**, Quinton D, Rutter ML (1984), Observation of parent child interaction with two to three year olds. *Journal of Child Psychology and Psychiatry*, 25:379-407.
10. **Mrazek DA**, Anderson IS, Strunk RC (1984), Disturbed emotional development of severely asthmatic preschool children. *Journal of Child Psychology and Psychiatry Book Supplement No. 4*, pp. 81-94.
11. Dowdney L, Skuse D, Rutter M, Quinton D, **Mrazek DA** (1984), Parenting qualities: Concepts, measures and origins. *Journal of Child Psychology and Psychiatry Supplement No.4*, pp. 19-42.
12. Strunk RC, **Mrazek DA**, Wolfson GS, LaBrecque JF (1985), Physiological and Psychological characteristics associated with deaths from asthma in childhood: A case controlled study. *Journal of the American Medical Association*, 254:1193-1198.
13. Dowdney L, Skuse D, Rutter M, Quinton D, **Mrazek DA** (1985), The nature and qualities of care provided by women raised in institutions. *Journal of Child Psychology and Psychiatry*, 26:599-625.

14. **Mrazek DA** (1985), Cystic fibrosis: A systems analysis of psychiatric consequences. *Advances in Psychosomatic Medicine*, 14:119-135.
15. **Mrazek DA** (1985), Childhood asthma: The interplay of psychiatric and physiological factors. *Advances in Psychosomatic Medicine*, 14:16-32.
16. **Mrazek DA** (1985), Childhood asthma: Two central questions for child psychiatry. *Journal of Child Psychology and Psychiatry*, 27:1-5.
17. Strunk RC, **Mrazek DA** (1986), Deaths from asthma in childhood: Can they be predicted? *Allergy Proceedings*, 7:454-461.
18. **Mrazek DA**, Casey B, Anderson I (1987), Insecure attachment in severely asthmatic preschool children: Is it a risk factor? *Journal of the American Academy of Child and Adolescent Psychiatry*, 26:516-520.
19. Bender B, Belleau L, Fukuhara J, **Mrazek DA**, Strunk RC (1987), Psychomotor adaptation in hospitalized asthmatic children. *Pediatrics*, 87:723-727.
20. **Mrazek DA** (1987), Avoiding behavioral problems in children with asthma. *The Journal of Respiratory Diseases*, 8:11-16.
21. Mrazek PJ, **Mrazek DA** (1987), Resilience in child maltreatment victims: A conceptual exploration. *Child Abuse and Neglect: The International Journal*, 11:357-366.
22. **Mrazek DA**, Miller BD (1987), The pediatric patient with severe asthma and psychiatric illness: Diagnostic and therapeutic considerations. *Seminars in Respiratory Medicine*, 8:347-52.
23. Linden MG, Bender BG, Harmon RJ, **Mrazek DA**, Robinson A (1988), 47.XXX: What is the prognosis? *Pediatrics*, 82:619-630.
24. Strunk RC, Fukuhara JT, LaBrecque JF, **Mrazek DA** (1989), Outcome of long term hospitalization for asthma in children. *Journal of Allergy and Clinical Immunology*, 83:17-25.
25. Gutstadt LB, Gillette JW, **Mrazek DA**, Fukuhara JT, LaBrecque JF, Strunk RC (1989), Determinants of school performance in children with chronic asthma. *American Journal of Diseases of Children*, 143:471-475.
26. Strunk RC, **Mrazek DA**, Fukuhara JT, Masterson J, Ludwick SK, LaBrecque JF (1989), Cardiovascular fitness in asthmatic children correlates with psychological functioning of the child. *Pediatrics*, 84:460-464.
27. Cyphers LH, Phillips K, Fulker DW, **Mrazek DA** (1990), Twin temperament during the transition from infancy to early childhood. *Journal of the American Academy of Child and Adolescent Psychiatry*, 29:392-397.
28. Klinnert MD, Miller BD, **Mrazek DA** (1990), Asthma fatalities: Who's at risk? *Contemporary Pediatrics*, 7:81-98.

29. **Mrazek DA**, Klinnert M, Mrazek P, Macey T (1991), Early asthma onset: Consideration of parenting issues. *Journal of the American Academy of Child and Adolescent Psychiatry*, 30:277-282. (This paper was judged to be among the top five papers published in this Journal during the 1990-1991 academic year by the Reiger Prize Committee and republished in *The 1992 Yearbook of Neonatal and Perinatal Medicine*, Chicago, Mosby.)
30. Shapiro T, **Mrazek DA**, Pincus H (1991), Current status of research in American child and adolescent psychiatry. I. A developmental analysis by age cohorts. *Journal of the American Academy of Child and Adolescent Psychiatry*, 30:443-448.
31. **Mrazek DA**, Shapiro T, Pincus H (1991), Current status of research in American child and adolescent psychiatry. II. A developmental analysis by age cohort. *Journal of the American Academy Child and Adolescent Psychiatry*, 30:1003-1008.
32. Klinnert M, Gavin LA, Wamboldt FS, **Mrazek D** (1992), Marriages with children at medical risk: The transition to parenthood. *Journal of the American Academy of Child and Adolescent Psychiatry*, 31:334-342.
33. Klinnert M, **Mrazek DA**, Mrazek P (1992), Quality of marital relationship: A clinical rating scale. *Psychiatry*, 55:132-145.
34. **Mrazek DA** (1992), Psychiatric complications of pediatric asthma. *Annals of Allergy*, 69:285-290.
35. Chatoor I, Kerzner B, Zorc L, Persinger M, Simenson R, **Mrazek D** (1992), Two year old twins refuse to eat: A multidisciplinary approach to diagnosis and treatment. *Journal of Infant Mental Health*, 13:252-268.
36. Steiner H, Fritz G, **Mrazek D**, Gonzales J, Jensen P (1993), Pediatric and psychiatric comorbidity, Part I: The future of consultation liaison psychiatry. *Psychosomatics*, 34 (2):107-111.
37. Schmitz S, Cherny S, Fulker D, **Mrazek D** (1994), Genetic and environmental influences on early childhood behavior. *Behavior Genetics*, 24:25-34.
38. Tanguay P, Bell J, Blotcky M, Donnelly C, Dunton D, Fischhoff J, Jensen P, McDermott J, **Mrazek D**, Pfeiffer C, Schowalter J, Shapiro T, Terr L (1994), What is the outcome for children's mental health needs in national health care reform? In: *Journal of the American Academy of Child and Adolescent Psychiatry: Sounding Board*, 33:9:1221-1222.
39. Klinnert M, **Mrazek DA**, Mrazek P (1994), Early asthma onset: The interaction between family stressors and adaptive parenting. *Psychiatry*, 57(1):51-61.
40. **Mrazek DA**, Mrazek P, Klinnert M (1995), The clinical assessment of parenting. *Journal of the American Academy of Child and Adolescent Psychiatry*, 34:3:272-282. (This paper was selected to be included in the *Annual Progress in Child Psychiatry and Child Development*, Vol. 29.)

41. Schmitz S, Fulker DW, **Mrazek DA** (1995), Problem behavior in early and middle childhood: An initial behavior genetic analysis. *Journal of Child Psychology and Psychiatry*, 36:1443-1458.
42. Chatoor I, Getson P, Menvielle E, Brasseaux C, O'Donnell R, Rivera Y, **Mrazek DA** (1997), A feeding scale for research and clinical practice to assess mother-infant interactions in the first three years of life. *Infant Mental Health Journal*, 18(1): 76-91.
43. Jensen PS, **Mrazek D**, Knapp PK, Steinberg L, Pfeffer C, Schowalter J, Shapiro T (1997), Evolution and revolution in child psychiatry: ADHD as a disorder of adaptation. *Journal of the American Academy of Child Adolescent Psychiatry*, 36(12): 1672-81.
44. **Mrazek DA**, Schuman W, Klinnert M (1998), Early asthma onset: Risk of emotional and behavioral difficulties. *Journal of Child Psychology and Psychiatry*, 39(2): 247-254.
45. **Mrazek, DA** (1998), The new genetic paradigm in child psychiatry. *Current Opinion in Psychiatry*, 11(4): 371-372.
46. Wamboldt MZ, Schmitz S, **Mrazek D** (1998), Genetic association between atopy and behavioral symptoms in middle childhood. *Journal of Child Psychology and Psychiatry*, 39(7):1007-16.
47. **Mrazek DA** (1999), Psychiatry. *Current Opinion in Pediatrics*, 10(4):363-364.
48. Lemery KS, Goldsmith HH, Klinnert MD, **Mrazek DA** (1999), Developmental models of infant and childhood temperament. *Developmental Psychology*, 35(1):189-204.
49. **Mrazek DA**, Klinnert M, Mrazek P, Rosenberg D, Ikle D, Brower A, McCormick D, Macey T, Rubin B, Larsen G, Jones J (1999), Prediction of early onset asthma in genetically at risk children. *Journal of Pediatric Pulmonology*, 27:85-94.
50. Lieberman D, **Mrazek DA** (1999), Outcome measures of psychiatric service delivery: How good are they? *Journal of Practical Psychiatry and Behavioral Health*, 5:153-159.
51. **Mrazek DA** (1999), New directions in child psychiatry. *Current Opinion in Pediatrics*, 11(4): 308-310.
52. Cao W, Tombran-Tink J, Chen W, **Mrazek DA**, Elias R, McGinnis JF (1999), Pigment epithelium-derived factor protects cultured retinal neurons against hydrogen peroxide-induced cell death. *Journal of Neuroscience Research*, 57:789-800.
53. Campo JV, Kingsley RS, Bridge J, and **Mrazek DA** (2000), Child and adolescent psychiatry in general children's hospitals: A survey of chairs of psychiatry. *Psychosomatics*, 41(2):128-133.
54. Pao M, Lyon M, D'Angelo LJ, Schuman WB, Tipnis T, **Mrazek DA** (2000), Psychiatric diagnoses in adolescents seropositive for the human immunodeficiency virus. *Archives of Pediatric and Adolescent Medicine* 154(3):240-4.

55. Jablonski MM, Tombran-Tink J, **Mrazek DA**, Iannaccone A (2000), Pigment epithelium-derived factor supports normal development of photoreceptor neurons and opsin expression after retinal pigment epithelium removal. *Journal of Neuroscience*, 19:7149-7157.
56. Chatoor I, Ganiban J, Hirsch R, Borman-Spurrell E, **Mrazek DA** (2000), Maternal characteristics and toddler temperament in infantile anorexia. *Journal of the American Academy of Child and Adolescent Psychiatry* 39(6):743-51.
57. Klinnert MD, Nelson HS, Price MR, Adinoff AD, Leung DYM, **Mrazek DA** (2001), Onset and persistence of childhood asthma: predictors from infancy. *American Academy of Pediatrics*, Vol. 108(4) 69.
58. Jablonski MM, Tombran-Tink J, **Mrazek DA**, Iannaccone A (2001), Pigment epithelium-derived factor supports normal Muller cell development and glutamine synthetase expression after removal of the retinal pigment epithelium. *Glia* 35(1):14-25.
59. Schmitz S and **Mrazek DA** (2001), Genetic and environmental influences on the associations between attention problems and other problem behaviors. *Twin Res.* 4(6):453-458.
60. Cao W, Tombran-Tink J, Elias R, Sezate S, **Mrazek DA**, McGinnis JF. (2001), In vivo protection of photoreceptors from light damage by pigment epithelium-derived factor. *Investigative Ophthalmology & Visual Science* 42(7):1646-52.
61. **Mrazek DA** (2001), A crisis in child psychiatric service delivery: why hasn't the piper been paid? *Mayo Clinic Proceedings* 76(11):1078-80.
62. Sampson SM and **Mrazek DA** (2001), Depression in adolescence. *Current Opinion in Pediatrics* 13(6):586-590.
63. **Mrazek DA** (2002), Leadership in child psychiatry: A perspective from a department chair. *Child and Adolescent Psychiatric Clinics of North America*, Vol. 11 (1) 103-112.
64. Barbaresi WJ, Katusic SK, Colligan RC, Pankratz VS, Weaver AL, Weber KJ, **Mrazek DA**, Jacobsen SJ (2002), How common is Attention-Deficit Hyperactivity Disorder? Incidence in a population-based birth cohort in Rochester, Minnesota, *Archives of Pediatric and Adolescent Medicine*, 156:217-224.
65. **Mrazek DA** and Agathen J (2002), Psychiatric disturbances in children of parents with bipolar disorder. *Journal of Psychiatric Practice* 8:196-204.
66. Vickers KS, Thomas JL, Patten CA and **Mrazek DA** (2002), Prevention of tobacco use in adolescents: Review of current findings and implications for health care providers. *Current Opinion in Pediatrics* 14(6):708-712.
67. **Mrazek DA** (2003), Psychiatric symptoms in patients with asthma causality, comorbidity, or shared genetic etiology. *Child Adol Psychiatric Clin N Am* 12:459-471.

68. Geda YE, Smith GE, Knopman DS, Boeve BF, Tangalos E, Ivnik RJ, **Mrazek D**, Edland S, Petersen RC (2004). De Novo Genesis of Neuropsychiatric symptoms in Mild Cognitive Impairment. *International Psychogeriatrics Journal* 16(1):1-10.
69. Karpyak VM, Rasmussen KG, Hammill SC, **Mrazek DA** (2004), Changes in Heart Rate Variability in Response to Treatment with electroconvulsive therapy. *JECT*. 20(2) 81-88.
70. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Pankratz VS, **Mrazek DA**, Jacobsen SJ (2004), How common is attention-deficit hyperactivity disorder? Towards resolution of the controversy: results from a population-based study, *Acta Paediatr Suppl*, 445:55-59.
71. **Mrazek DA** (2004), Genotyping makes prescribing safer. *Current Psychiatry* 3(9): 11-23.
72. **Mrazek DA** (2005), Clinical implementation of psychiatric pharmacogenomics testing. *Personalized Medicine* 2(2): 93-95.
73. **Mrazek DA** (2005), Pharmacogenomic DNA chip: Test anticipates adverse response to medication. *Current Psychiatry* 4(7): 67-73.
74. Unal SS, Port JD, **Mrazek DA** (2005), Magnetic resonance spectroscopic studies of pediatric mood disorders: a selective review. *Current Opinion in Pediatrics*. 17(5): 619-625.
75. Geda YE, Knopman DS, **Mrazek DA**, Edland SD, Jicha GA, Smith GE, Negash S, Boeve BF, Ivnik RJ, Petersen RC, Rocca WA. (2006), Depression, *Apolipoprotein E* Genotype and the Incidence of Mild Cognitive Impairment: A Prospective Cohort Study. *Archives of Neurology* 63(3): 435-440.
76. **Mrazek DA** (2006), The context of genetic testing in clinical psychiatric practice. *CNS Spectrums* 11(3): 3-4.
77. **Mrazek DA**. (2006), Psychiatric pharmacogenomics. *Focus IV* (3): 339-343.
78. **Mrazek, DA** (2007) Current applications of clinical genetic testing for psychiatric practice. *MN Medicine*, 90(1): 42-43.
79. Black JL, O'Kane DJ, **Mrazek DA** (2007), The impact of CYP allelic variation on antidepressant metabolism: a review. *Expert Opin. Drug Metab.Toxicol.*3(1): 21-31.
80. McAlpine DE, O'Kane DJ, Black JL, **Mrazek DA** (2007), Cytochrome P450 2D6 Genotype Variation and Venlafaxine Dosage. *Mayo Clinic Proceedings* 82(9):1065-1068.
81. Mrazek MD, Koenig BA, Skime M, Snyder, K, Hook CC Black, JL, **Mrazek DA** (2007) Assessing attitudes about genetic testing as a component of continuing medical education. *Academic Psychiatry*, 31(6):447-451.

82. Port JD, Unal SS, **Mrazek DA**, Marcus SM. (2008), Metabolic alterations in medication-free patients with bipolar disorder: A 3T CSF-corrected magnetic resonance spectroscopic imaging study. *Psychiatry Research: Neuroimaging*, 162(3):113-121.
83. Faulkner LR, Tivnan, PW, Winstead DK, Reus VI, Andrade NN, Brooks BA, Colenda CC, **Mrazek DA**, Reifler BV and Schneidman B. (2008) The ABPN Maintenance of Certification Program for Psychiatrists: Past history, current status and future directions. *Academic Psychiatry* 32(3):241-248.
84. Karpyak VM, Hall-Flavin DK, **Mrazek DA**. (2008) Can genetics predict risk for alcohol dependence? *Current Psychiatry* 7(3):57-73.
85. **Mrazek DA**, Rush J, Biernacka J, O’Kane D, Cunningham J, Wieben E, Schaid D, Drewes M, Courson V, Snyder K, Black JL, III, Weinshilboum RM. (2008) SLC6A4 variation and citalopram response. *Neuropsychiatric Genetics* (in press).
86. Unal SS, Port JD, Felmlee JP, **Mrazek DA**, Marcus SM. (2008), Metabolic alterations detected with 3 Tesla: Cerebrospinal fluid corrected magnetic resonance spectroscopic imaging in medication-free patients with bipolar disorder. *Psychiatry Research/Neuroimaging*. (in press).
87. Mohny BG, Mckenzie JA, Capo JA, Nusz KJ, **Mrazek D**, Diehl NN. (2008) Mental illness in young adults who had strabismus as children. *Pediatrics* (in press).

#### **B. Book Chapters**

1. Gaensbauer TJ, **Mrazek DA**, Harmon RJ (1980), Emotional expression in abused and/or neglected infants. In: Psychological Approaches to Child Abuse, ed. N Frude. London: Batsford Academic and Educational Ltd., pp. 120-135.
2. **Mrazek DA**, Mrazek PB (1981), Psychosexual development of the family. In: Sexually Abused Children and their Families, eds. PB Mrazek and CH Kempe. New York: Pergamon Press, pp. 17-32.
3. Mrazek PB, **Mrazek DA** (1981), The effects of child sexual abuse: Methodological considerations. In: Sexually Abused Children and their Families, eds. PB Mrazek and CH Kempe. New York: Pergamon Press, pp. 235-245.
4. **Mrazek DA** (1984), Effects of hospitalization on early child development. In: Continuities and Discontinuities in Development, eds. R Emde and R Harmon, New York: Plenum, pp.211-225.
5. **Mrazek DA** (1985), Child psychiatric consultation and liaison to pediatrics. In: Child Psychiatry: Modern Approaches, Second Edition, eds. M Rutter and L Hersov. London: Blackwell, pp. 888-899.
6. **Mrazek DA**, Mrazek PJ (1985), Child maltreatment. In: Child Psychiatry: Modern Approaches, Second Edition, eds. M Rutter and L Hersov. London: Blackwell, pp. 679-697.

7. **Mrazek DA** (1986), Pediatric hospitalization: Understanding the stress on families from a developmental perspective. In: The Psychosomatic Approach: Contemporary Practice of Whole-Person Care, ed. M Christie. Chichester: John Wiley and Sons, pp. 91-111.
8. **Mrazek, DA** Klinnert M (1988), The psychological and psychiatric evaluation of asthmatic children. In: Handbook of Child Health Assessment, ed. P Karoly. New York: John Wiley and Sons, pp. 410-433.
9. **Mrazek DA** (1988), Asthma: Psychiatric considerations, evaluation, and management. In: Allergy: Principles and Practice, 3rd Edition, eds. E Middleton, CE Reed, and EF Ellis. St. Louis: C. V. Mosby, pp. 1176-1196.
10. **Mrazek DA**, Klinnert M (1991), Asthma: Psychoneuroimmunological considerations. In: Psychoneuroimmunology II, eds. R Ader, DL Felten, and N Cohen. Orlando: Academic Press, pp. 1013-1035.
11. **Mrazek DA** (1991), Chronic pediatric illness and multiple hospitalizations. In: Child and Adolescent Psychiatry: A Comprehensive Textbook, ed. M Lewis. Baltimore: Williams and Wilkins, pp. 1041-1050.
12. **Mrazek DA** (1993), Asthma: Stress, allergies, and the genes. In: Mind/Body Medicine, eds. D Goleman, J Gurin. New York: Consumer Reports, pp. 193-205.
13. **Mrazek DA** (1993), Psychosomatic processes and physical illnesses. In: Handbook of Infant Mental Health, ed. C Zeanah. New York: Guilford, pp. 350-358.
14. **Mrazek DA** (1994), Disturbed emotional development in severely asthmatic children. In: Assessment of Quality of Life in Childhood Asthma, eds. M Christie and D French. Chur, Switzerland: Harwood Academic Publishers, pp. 71-80.
15. **Mrazek DA** (1994), Psychiatric aspects of somatic disease and disorders. In: Child and Adolescent Psychiatry, Third Edition, eds. M Rutter, L Hersov, and E Taylor. Oxford: Blackwell, 697-710.
16. **Mrazek DA**, Krener P (1995), Child and adolescent psychopathology. In: Core Readings in Psychiatry, An Annotated Guide to the Literature, Second Edition, ed. M Sacks, WH Sledge, and C Warren. Washington, D.C.: American Psychiatric Association Press, pp. 373-400.
17. Krener P, **Mrazek DA** (1995), Modalities in child and adolescent psychiatry. In: Core Readings in Psychiatry, An Annotated Guide to the Literature, Second Edition, ed. M Sacks and WH Sledge, and C Warren. Washington, D.C.: Psychiatric Association Press, p. 621-646.
18. **Mrazek DA**, Klinnert M (1996), Emotional stress and the onset of asthma. In: Intense Stress and Mental Disturbance in Children, ed. CR Pfeffer. Washington, D.C.: American Psychiatric Press, Inc., pp. 211-224.
19. **Mrazek DA** (1996), A psychiatric perspective on human development. In: Psychiatry, eds. A Tasman, J Kay, and J Lieberman. Philadelphia: W.B. Saunders, pp. 63-74.

20. **Mrazek DA** (1996), Chronic pediatric illness and multiple hospitalizations. In: Child and Adolescent Psychiatry: A Comprehensive Textbook, 2nd edition, ed. M Lewis. Baltimore: Williams and Wilkins, pp. 1058-1066.
21. **Mrazek DA** (1997), The asthmatic child. In: The Handbook of Child and Adolescent Psychiatry, ed. J Noshpitz. Washington, D.C.: John Wiley & Sons, pp. 290-296.
22. **Mrazek DA** (1997), The allergic child. In: The Handbook of Child and Adolescent Psychiatry, ed. J Noshpitz. Washington, D.C.: John Wiley & Sons, pp. 285-290.
23. Theut SK, **Mrazek DA** (1997), Infants and toddlers with medical conditions and their parents: Reactions to illness and hospitalization and models for intervention. In: The Handbook of Child and Adolescent Psychiatry, ed. J Noshpitz. Washington, D.C.: John Wiley & Sons.
24. **Mrazek DA** (1997), Psychological aspects in children and adolescents. In: Asthma, Vol. 2, eds. P Barnes, A Leff, M Grunstein, and A Woolcock. Philadelphia, Pennsylvania. Lippincott-Raven, pp. 2177-2183.
25. **Mrazek DA** (1999), Psychosomatic processes and physical illnesses. In: Handbook of Infant Mental Health, ed. C Zeanah. New York, NY: Guilford Publications, Inc., pp. 425-436.
26. **Mrazek DA** (2001), Psychiatric aspects of somatic disease and disorders. In: Child and Adolescent Psychiatry, Fourth Edition, eds. M Rutter and E Taylor. Oxford: Blackwell, pp. 810-827.
27. **Mrazek DA** (2002), Chronic pediatric illness and multiple hospitalizations. In: Child and Adolescent Psychiatry: A Comprehensive Textbook, Third Edition, ed. M Lewis. Baltimore, Maryland, Lippincott Williams and Wilkins, pp. 1230-1238.
28. **Mrazek DA** (2002), A psychiatric perspective on human development. In: Psychiatry, Second Edition, eds. A Tasman, J Kay, and J Lieberman, Philadelphia: W.B. Saunders, pp. 77-90.
29. **Mrazek DA** (2004), Clinical Genomic Testing. In: Textbook of Child and Adolescent Psychiatry, Third Edition, ed. J Wiener and M Dulcan. American Psychiatric Publishing, Inc., pp. 193-203.
30. **Mrazek DA** and Mrazek PJ (2005), Prevention of psychiatric disorders in children and adolescents. In: Comprehensive Textbook of Psychiatry, Eighth Edition, eds: B Sadock and V Sadok. Lippincott Williams & Wilkins, pp. 3513-3519.
31. **Mrazek DA** (2006), Molecular genetic testing. In: Neurological Therapeutics: Principles and Practice, 2<sup>nd</sup> Edition, Martin Dunitz, pp. 25-30.
32. **Mrazek DA** and Rasimas JJ (2006), Genomic testing. In: Psychosomatic Medicine in the 21<sup>st</sup> Century, Lippincott Williams & Wilkins, pp. 899-905.
33. **Mrazek DA** and Mrazek PJ (2007), Prevention of Psychiatric Disorders. In: Lewis's Child and Adolescent Psychiatry: A Comprehensive Textbook, Lippincott Williams & Wilkins, pp. 171-177.

34. Hernan SI, Acuna M, Alarcon R, Karpyak V, Lemanda V, **Mrazek DA**, Novoa F, Valenzuela C. (2007) Farmacogenomica psiquiatrica: actualizacion y perspectivas. In: Genetica y Farmacogenomica en Psiquiatria. C&C Ediciones, Santiago, Chile, pp. 59-79.
35. **Mrazek DA** (2008), A Psychiatric Perspective on Human Development. A Developmental Perspective on Normal Domain of Mental and Behavioral Functions. In: Psychiatry, Third Edition, ed., A. Tasman, J. Kay, J. Lieberman, M. First and M. Maj. Pp. 97-108.

#### C. Books

1. **Mrazek DA**, Garrison W (1993), A to Z Guide to Your Child's Behavior. Perigee Books, New York.
2. Jensen PS, Knapp, P, **Mrazek DA** (2006), Toward a New Diagnostic System for Child Psychopathology. Moving Beyond the DSM. Guilford Press, New York.
3. **Mrazek DA**. (2008), Psychiatric Pharmacogenomics. Oxford University Press, New York

#### D. Published Abstracts

1. Gaensbauer TJ, **Mrazek DA** (1978), Emotional expression in abused/neglected infants. *Proceedings of the Second International Congress on Child Abuse and Neglect*, London, England, p. 86.
2. **Mrazek DA** (1981), Early emotional development in severely asthmatic preschool children. *Proceedings of the 6th World Congress of Psychosomatic Medicine*, p. 37.
3. **Mrazek DA** (1981), Child psychosis and asthma. *Proceedings of the 6th World Congress for Psychosomatic Medicine*, p. 46.
4. **Mrazek DA**, Anderson IS, Strunk RC (1982), Disturbed emotional development in severely asthmatic preschool children. *Proceedings of the 10th International Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions*, p. 52.
5. Dowdney L, Skuse D, Rutter M, Quinton D, **Mrazek DA** (1982), The nature and qualities of aid provided by women raised in institutions. *Proceedings of the 10th International Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions*, p. 57.
6. **Mrazek DA**, Anderson I, Klinnert MD, Sefler S, Strunk P (1983), Behavioral effects of theophylline on preschool asthmatic children. *Scientific Proceedings for the Annual Meeting of the American Academy of Child and Adolescent Psychiatry*.
7. **Mrazek DA**, Strunk RC (1984), Psychological adjustment of severely asthmatic preschool children: Allergic considerations. *Psychosomatic Medicine*, 46:85.

8. Miller BD, Carson J, Casey BD, Cousins P, Miller M, **Mrazek DA** (1984), Consultation/liaison in the home environment: An extended family for the asthmatic child. *Psychosomatic Medicine*, 46:81.
9. Strunk RC, Wolfson GS, LaBrecque JF, **Mrazek DA** (1984), Predictors of a fatal outcome in childhood asthma. *Proceedings of the Annual Meeting of the American Academy of Allergy and Immunology*, p. 78.
10. **Mrazek DA** (1984), Medical neglect of severe asthma: Fatal consequences. *Proceedings of the Fifth International Congress on Child Abuse and Neglect*, Montreal, Quebec, p. 21.
11. **Mrazek DA** (1985), Psychiatric illness in severely asthmatic children. *Papers on New Research American Psychiatric Association*, p. 112.
12. **Mrazek DA**, Masterson J (1985), Family global assessment scale (FGAS): Initial reliability and validity. *Scientific Proceedings for the Annual Meeting of the American Academy of Child and Adolescent Psychiatry*, p. 38.
13. **Mrazek DA**, Casey B, Anderson I (1985), Quality of attachment: Is it as easy as A, B, C? *Scientific Proceedings for the Annual Meeting of the American Academy of Child Psychiatry*, p. 20.
14. Klinnert M, Miller BD, LaBrecque J, Strunk RC, **Mrazek D** (1985), Psychological and social problems in severely asthmatic children. *Scientific Proceedings for the Annual Meeting of the American Academy of Child and Adolescent Psychiatry*, p. 37-38.
15. Strunk RC, **Mrazek DA**, Masterson J, Fukuhara J, Ludwick SK (1986), Cardiovascular fitness in asthmatic children correlates with psychological functioning but not illness severity. *The Society for Pediatric Research*, p. 18.
16. **Mrazek DA**, Masterson J, Fukuhara JT, Strunk RC (1986), Severe asthma in children and adolescents: What are the psychiatric implications? *Scientific Proceedings for the Annual Meeting of the American Academy of Child and Adolescent Psychiatry*, p. 41.
17. **Mrazek DA** (1986), The interaction of risk factors: What really is pathogenic? *Scientific Proceedings for the Annual Meeting of the American Academy of Child and Adolescent Psychiatry*, p. 32.
18. **Mrazek DA**, Mrazek PJ, Klinnert M, Anderson I, Bzdek S (1986), Documenting the initial mother-child experience: Are clinical scales useful? *Scientific Proceedings for the Annual Meeting of the American Academy of Child and Adolescent Psychiatry*, p. 13.
19. Lerner JA, **Mrazek DA**, Strunk RC (1986), Prednisone use increases the risk of psychiatric disturbance in asthmatic children. *Scientific Proceedings for the Annual Meeting of the American Academy of Child and Adolescent Psychiatry*, p. 14.
20. **Mrazek DA** (1986), Psychological risk factors for asthmatic children. *Proceedings of the North Queensland Medical Conference*, p. 54.

21. Fritz G, Pumariega, A, Krener P, Miller B, Kovacks M, **Mrazek D** Marsh J (1987), Depression and chronic illness in children and adolescents. *American Academy of Child and Adolescent Psychiatry Scientific Proceedings of the Annual Meeting*, p. 31.
22. **Mrazek DA**, Klinnert MD, Anderson IS (1987), Smoking among asthmatics. *Epidemiological Research Exchange*, p. 11.
23. Klinnert MD, **Mrazek DA** (1988), Temperament and illness in infants. *Proceedings of The International Conference on Infant Studies*, p. 9.
24. **Mrazek DA**, Klinnert MD (1988), Measurement of psychopathology in young preschool children. *Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry with the Canadian Academy of Child Psychiatry*, 4:60.
25. Dibble E, Tanguay P, **Mrazek D**, Shaffer D, Boxer A, Cohen D (1988), N.I.M.H. research training and career development support. *Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry with the Canadian Academy of Child Psychiatry*, 4:34.
26. **Mrazek DA**, Klinnert M, Anderson I, Macey T, Mrazek PJ (1988), Prediction of early developmental psychopathology. *Society for Research in Child Development Abstracts*, 6:154.
27. **Mrazek DA**, Klinnert M (1989), The relationship of maternal modulation of infant affect and infant temperament. *Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry*, 4:48.
28. **Mrazek DA**, Klinnert M, Mrazek P, Rubin B, Anderson I, Brower A (1989), Stress and recurrent wheezing: Differential effects for asthma and infection. *Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry*, 5:80.
29. **Mrazek DA**, Pauls D, Anderson I, Brower A, Klinnert M (1989), Segregation analysis of asthmatic families. *American Journal of Human Genetics*, 45:245.
30. **Mrazek DA**, Klinnert MD (1990), The effects of family life events on asthma onset. *Psychosomatic Medicine*, 52:229.
31. **Mrazek DA**, Klinnert M (1990), Predictive capacity of elevated Serum IgE for early asthma onset. *Journal of Clinical Immunology*, 85:194.
32. Klinnert MD, **Mrazek DA** (1990), The origin of asthma in the context of the mother-infant relationship. *Infant Behavior and Development (ICIS Issue)*. 13:85.
33. **Mrazek DA**, Klinnert M, Mrazek P, Anderson I, Brower A (1990), Early asthma onset: The link between life events, maternal modulation of stressors, and disease expression. *Program and Proceedings of the Developmental Psychobiology Research Group Sixth Biennial Retreat*, p. 33.
34. **Mrazek DA**, Klinnert M, Russell C (1990), Early asthma onset: Is breast-feeding protective? *Program and Proceedings of the Developmental Psychobiology Research Group Sixth Biennial Retreat*, p. 34.

35. Rubin BC, Klinnert MD, Rosenberg DM, Brower A, Landow C, Young K, McCormick D, **Mrazek DA** (1990), The role of maternal sensitivity and affect regulation in the development of attachment. *Program and Proceedings of the Developmental Psychobiology Research Group Sixth Biennial Retreat*, p. 39.
36. Rubin BC, Klinnert MD, **Mrazek DA** (1990), The relationship of attachment to the development of early childhood psychopathology. *Program and Proceedings of the Developmental Psychobiology Research Group Sixth Biennial Retreat*, p. 40.
37. **Mrazek DA**, Klinnert M, Brower A (1990), Early asthma onset: Evidence for the dual pathway hypothesis. *Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry*, 6:71.
38. Rubin B, Klinnert M, **Mrazek DA** (1990), Security of attachment: Is it predictive of asthma onset and developmental psychopathology? *Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry*, 6:71.
39. Klinnert MD, Mrazek P, Brower A, **Mrazek DA** (1991), Psychopathology as a risk factor for asthma in 3-year-olds. *Abstracts of the 1991 Biennial Meeting of the Society for Research in Child Development*, 8:327.
40. **Mrazek DA**, Klinnert M (1991), Early identification of asthma subtypes. *Psychosomatic Medicine*, 53:233.
41. Klinnert M, Gavin LA, Wamboldt FS, **Mrazek D** (1991), Marital change after the birth of an at-risk child. *New Research Program and Abstracts, American Psychiatric Association 144<sup>th</sup> Annual Meeting*, p. 108.
42. **Mrazek DA**, Pauls D, Brower A, McCormick D, Young K, Klinnert M (1991), Segregation analysis of 146 asthmatic families by asthma subtype. *Proceedings of the 8th International Congress of Human Genetics*, p. 152.
43. Rubin B, **Mrazek DA**, Klinnert M, Young K, McCormick D (1992), The relationship of attachment to the development of early childhood psychopathology. *Infant Behavior and Development (ICIS Issue)*, 15:674.
44. Rosenberg DM, Rubin B, Dunhill C, **Mrazek DA** (1992), Maternal continuity and child outcomes in socioemotional development. *Infant Behavior and Development (Special ICIS Issue)*, 15:667.
45. **Mrazek DA** (1992), Familial risk factors associated with the genetic expression of asthma in young children. *American Psychiatric Association CME Syllabus and Proceedings Summary*, p. 61.
46. **Mrazek DA** (1992), Intense stress and mental disturbance in children. *Presented at America Psychiatric Association CME Syllabus and Proceedings Summary*, p. 267.
47. Mascali J, Rosenwasser L, **Mrazek DA**, Borish L (1992), Absence of polymorphisms detectable by RFLP between normal and atopic subjects in the IL-4 gene promoter. *Journal of Allergy and Clinical Immunology*, 89:219.

48. Divino C, **Mrazek DA**, Klinnert M, Rubin B, Rosenberg D (1992), The development of affect regulation in infants and young children. *Scientific Proceedings of the World Association of Infant Psychiatry and Allied Disciplines, Fifth World Congress, September 9-13, 1992.*
49. Klinnert, M. D., **Mrazek, D. A.**, and Mrazek, P. (1993), Psychological contributions to onset of asthma in three-year olds. *Scientific Proceedings of the 60th Anniversary Meeting of the Society for Research in Child Development, New Orleans, Louisiana.*
50. Rubin BC, Klinnert MD, **Mrazek DA** (1993), Continuities in attachment, the capacity for relatedness, and the representation of relationships in three year olds. *Scientific Proceedings of the 60<sup>th</sup> Anniversary Meeting of the Society for Research in Child Development, New Orleans, LA.*
51. Klinnert M, Lanthier M, Bryant B, **Mrazek DA** (1993), Temperament as a predictor of preschool behavior problems. *Scientific Proceedings of the 40th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry, p. 40.*
52. Klinnert MD, Nelson HS, Leung DYM, **Mrazek DA** (1994), The relative contribution of allergy and psychological factors to childhood asthma. *Abstracts of the American Academy of Allergy and Immunology, 1994.*
53. Klinnert MD, **Mrazek DA**, Mrazek P, Walker D (1994), The relationship between stress and respiratory illness in young infants. Poster presented at the International Conference on Infant Studies, Paris, France.
54. Klinnert MD, McCormick DR, **Mrazek DA** (1994), Behavior problems in young children: Parent, teacher and clinician perspectives. *Scientific Proceedings of the Annual AACAP Meeting, Vol. X, p. 67.*
55. Rivera Y, Menvielle E, Hodder L, **Mrazek DA** (1994), Secure attachment in a Central American immigrant population. *Scientific Proceedings of the Annual AACAP Meeting, Vol. X, p. 68.*
56. **Mrazek DA**, Klinnert MD (1994), A progress report on the W.T. Grant asthma risk study. *Scientific Proceedings of the Annual AACAP Meeting, Vol.X, p. 83.*
57. McQuaid EL, Walker D, **Mrazek DA** (1994), Family predictors to asthma adjustment in young children. *Scientific Proceedings of the Annual AACAP Meeting, Vol. X, p. 83.*
58. Rubin SG, Rivera Y, Menvielle E, Hodder LL, **Mrazek DA** (1994), Risk factors for Central American mothers and infants. Presented at 4th Annual National Conference on Prevention Research, Washington, D.C., Nov. 10-12, 1994.
59. Mrazek P, **Mrazek DA**, Klinnert M (1994), A selective preventive intervention research program using medical and psychosocial outcome assessment. Presented at 4th Annual National Conference on Prevention Research, Washington, D.C., Nov. 10-12, 1994.
60. Pao M, **Mrazek D**, Brown L, Ponton L (1996), Adolescents and the HIV epidemic: What is the psychiatrist's role? *Scientific Proceedings of the Annual American Academy of Child and Adolescent Psychiatry Meeting, Vol. XII.*

61. Pao M, Tipnis T, **Mrazek DA**, D'Angelo L (1997), Depression screening in a primary care adolescent clinic. *Children's Research Institute 10th Annual Advances in Pediatrics: Educational and Scientific Forum, May 21, 1998*. Children's National Medical Center, Washington, D.C.
62. Butt NK, **Mrazek DA**, Tombran-Tink J (1998), Expression of dynamin I and munc-18 in retinal pigment epithelium cells. *J. IOVS 39(4) S725*.
63. Tombran-Tink J, Butt NK, **Mrazek DA** (1998), Retinoic acid regulates the expression of pigment epithelium-derived factor (PEDF) in cultured RPE cells. *J. IOVS 39(4) S735*.
64. **Mrazek DA** (1998), Environmental prevention strategies for genetically vulnerable children. *Scientific Proceedings of Society for Prevention Research 6<sup>th</sup> Annual Meeting*.
65. Tchabo NE, Schuman WB, Klinnert MD, **Mrazek DA** (1998), Early psychosocial risk factors associated with asthma onset. *Scientific Proceedings of the Annual American Academy of Child and Adolescent Psychiatry Meeting, Vol. XIV*.
66. **Mrazek DA**, Klinnert M, Mrazek, PJ (1999), An early parenting intervention for children at risk. *Scientific Proceedings of the Society for Prevention Research 7<sup>th</sup> Annual Research Conference*, p.153.
67. **Mrazek DA** (1999), The new genetic paradigm: applications to preventive intervention research. *Scientific Proceedings of the Society for Prevention Research 7<sup>th</sup> Annual Research Conference*, p. 47.
68. Mrazek M, Butt NK, Tink JT and **Mrazek DA** (1999), Behavioral influences on aggressive behavior in SJL/J male mice. *5<sup>th</sup> Annual GW Health Sciences Research Day*, p. 9.
69. **Mrazek DA** (1999), The asthma intervention project: a randomized controlled trial. George Washington University Medical Center, *5<sup>th</sup> Annual GW Health Sciences Research Day*, March 10, 1999.
70. Cao W, Tombran-Tink J, Elias R, Sezate S **Mrazek D**, and McGinnis JF (2000), In vivo protection of photoreceptors from light damage by pigment epithelium-derived factor. *Investigative Ophthalmol. Vis. Sci.* 41 (4):S20:103-B103.
71. Jablonski MM, Tombran-Tink J, **Mrazek DA** and Ervin CS (2000), PEDF Protects photoreceptors from degeneration and induces opsin expression after RPE Detachment. *Investigative Ophthalmol. Vis. Sci.* 41 (4):S332:1747.
72. Wohabrebbi A, Tombran-Tink J, **Mrazek DA**, Ervin CS, & Jablonski MM (2000), PEDF prevents Muller Cell Degeneration Induced by RPE Detachment. *Investigative Ophthalmol. Vis. Sci.* 41 (4):S850:4516-B463.
73. **Mrazek DA** (2002), Genomic identification of children at risk for psychiatric disorders. *AACAP Scientific Proceedings*, p.59.
74. Barbaresi WJ, Katusic SK, Colligan RC, Pankratz VS, Weaver AL, **Mrazek DA**, Agathen JM, Jacobsen, SJ (2002), Psychopharmacologic treatment of AD/HD in a population-based birth cohort. *Pediatric Res 2002 Apr*, 51 (4 Part 2): 458A

75. Hall-Flavin DK, Black JL, **Mrazek DA**, Sanchez-Samper X (2002). Screening of patients who drink on disulfiram for atypical P450 polymorphisms: A pilot study. *Am J Med Genet 2002 Oct 8*; 114(7):780.
76. Hall-Flavin DK, Black JL, **Mrazek DA** (2002). The difference between liking and needing: Genetic influences in the ontogeny of addiction. *Am J Med Genet 2002 Oct 8*; 114(7):780.
77. Hall-Flavin DK, Lewis DT, **Mrazek DA** (2002). Developing a scale to examine the relationship between developmental events, psychiatric illness, and medical comorbidity in addicted populations: A pilot study. *Am J Med Genet 2002 Oct 8*; 114(7):779-780.
78. **Mrazek DA** (2002), Interventions designed to change parenting behavior. *American Academy of Child and Adolescent Psychiatry Scientific Proceedings*, p.4.
79. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, **Mrazek DA**, and Jacobsen SJ (2003). School dropout and grade retention among children with ADHD: A population-based birth cohort study. *Pediatr Res 2003 Apr*; 53 (4 Part 2): 65A-66A.
80. Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, **Mrazek DA**, and Jacobsen SJ (2003), Substance abuse among ADHD cases: A population-based birth cohort study. *Pediatr Res 2003 Apr*; 53(4 Part 2):65A.
81. Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, **Mrazek DA**, and Jacobsen SJ (2003), The impact of psychostimulant treatment on drug/alcohol abuse among children with AD/HD. *Society for Developmental and Behavioral Pediatrics*, Pittsburgh, PA, September 18-22.
82. **Mrazek DA**, Black JL III, and O’Kane D (2003), Pharmacogenomic screening for antidepressant medication selection. *Am J Med Genetics 122B* (1):38.
83. **Mrazek DA** (2003), Ethical issues involving genomic evaluation and treatment of child psychiatric patients. *American J. Medical Genetics 122B*(1):38 and *Adolescent Psychiatry Scientific Proceedings*, p. 57.
84. Louikianova LL, Hall-Flavin DK, Bostwick JM, Black JL, **Mrazek DA** (2003), Relevance of personality genetics for vulnerability to alcoholism: methodological issues – a review. 26<sup>th</sup> Annual Meeting of the Research Society on Alcoholism
85. Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, **Mrazek DA**, Jacobsen S (2003), Treatment with psychostimulants is associated with decreased rates of substance abuse and improved school outcomes among children with ADHD. Abstract/Poster. Presented at the International Society for Pharmacoeconomics and Outcomes Research 6<sup>th</sup> Annual European Congress, Barcelona, Spain
86. Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, **Mrazek DA**, and Jacobsen SJ (2004), The impact of psychostimulant treatment on substance abuse among ADHD cases with learning disability and/or psychiatric comorbidities. *Pediatr Res*, Apr; 55 (4 Suppl S Part 2):1A.

87. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, **Mrazek DA**, Jacobsen SJ. (2004), Co-morbidities among children with ADHD: Perspectives from a population-based study. *Pediatr Res*, Apr; 55(4 Suppl S Part 2):1A.
88. Moore BE, Mathiesen DA, Dukek BA, **Mrazek DA**, O’Kane DJ (2004), Evaluation of an “In-House” Cytochrome P450 assay on an open platform: the potential for allelic drop-out. *Clinical Chemistry* 50(6 Suppl S Part 2):A111.
89. Mathiesen DA, Moore BE, Bruflat JK, Lagerstedt A, Rand BA, Dukek BA, Fisher PK, **Mrazek DA**, O’Kane DJ (2004), Validation of the TmBioscience Tag-It™ P450-2D6 Assay on the Luminex® 100 xMAP System, *Clinical Chemistry* 50(6 Suppl S Part 2)A120-1.
90. **Mrazek DA**, O’Kane DJ, Snyder KA, Black JL (2004), 138, The pharmacogenomic assessment of patients with side effects to antidepressant medications. *Biol Psychiatry* 55(8S-Suppl):40S.
91. Loukianova LL, Hall-Flavin DK, Schneekloth TD, **Mrazek DA** (2004). Neurobiology of Motivational Drive and Self-Control: Towards Understanding Etiology of Drug Addiction. *ISAM Annual Meeting*, Helsinki, Finland, June 2-5, 2004.
92. Gee SS, Lee EK, Ireland J, Geda YE, **Mrazek DA** (2004). Chromosome 10q translocation in a patient with schizophrenia: a case report. *American Psychiatric Association 157<sup>th</sup> Annual Meeting*, New York, NY, May 1-6, NR109, pp. 8.
93. Loukianova LL, Hofmann VE, **Mrazek DA**, Hall-Flavin DK (2004). Drug addiction and ADHD: Perspectives on Prevention and Treatment. *J. Addictive Diseases* 23(2):143.
94. Port JD, Unal SS, Maroney-Smith MJ, Felmlee JP, **Mrazek DA** (2004). Imaging Markers of Bipolar Disease: Evaluation of Proton Magnetic Resonance Imaging at 3T. *Radiological Society of North America*, p. 440.
95. Moore BE, Mathiesen BA, Dukek DA, **Mrazek DA**, O’Kane DJ, (2004). Evaluation of “In House” Cytochrome P450 Assay on an Open Platform: the Potential for Allelic Drop-out. *Clinical Chemistry* 50(6 Suppl S Part 2):A111.
96. Bhagia J, Westergren BA, **Mrazek DA**, (2004) Tricyclic antidepressant fatality in children: consideration of 2D6 genotype. *American Academy of Child and Adolescent Psychiatry Scientific Proceedings*, p. 150.
97. **Mrazek, DA**, (2005) Pharmacogenomic Model for Antidepressant Response. (Abstract 608). *Biol. Psychiatry* Apr; 57(8S):167S.
98. Port JD, Unal SS, Maroney-Smith MJ, Felmlee JP, **Mrazek DA** (2005). Imaging Markers of Bipolar Disease: Evaluation of Proton Magnetic Resonance Spectroscopic Imaging at 3T. *Biol Psychiatry* 57(8S):101S.
99. **Mrazek DA**, O’Kane DJ, Snyder KA (2005). A Two-Gene Pharmacogenomic Model for Antidepressant Response. *Royal College of Psychiatrists Annual Meeting*, Edinburgh, UK, June.

100. Karpyak V., Hall-Flavin D., Schneekloth T., Loukianova L., **Mrazek DA** (2005). An Electronic Database for a New Intensive Outpatient Addictions Treatment Program. *Proceedings of the 28<sup>th</sup> Annual Meeting of the Research Society on Alcoholism* 29(5):114A.
101. Rand A., Dukek B., **Mrazek DA**, O’Kane D. (2005). Microfluidics-based Assay for Polymorphisms in the Serotonin Transporter (Abstract D-104). *Clin. Chem.* 51 (6 Suppl):A188.
102. Unal S, **Mrazek DA**, Port JD (2005), <sup>1</sup>H-MRS and <sup>31</sup>P-MRS correlates of early onset bipolar disorder in dorsolateral prefrontal and anterior cingulate cortex. *Proceedings of the Annual Meeting of the American Society of Neuroradiology*: 118-119.
103. Llerena A, **Mrazek DA**. (2006), Personalized prescription has arrived in psychiatric clinical practice: CYP2D6 and CYP2C19 genotyping. *Biol Psychiatry* 59(8S Suppl):3S.
104. **Mrazek DA**. (2006), Are the 5HT transporter and/or the P450 isoenzyme genes associated with response/remission to citalopram? *Biol Psychiatry* 59(8S Suppl):105S.
105. Hall-Flavin D, Karpyak V, Vander Weg M, Schneekloth T, **Mrazek D** (2006), The use of Acamprosate in a Clinical Population: Initial Mayo Clinic Experience. *Res. Soc. on Alcoholism* 30:106A.
106. Vander Weg MW, Karpyak VM, Hall-Flavin D, Schneekloth T, Loukianova LL, Drews MS, **Mrazek DA** (2006), Comparability of the Penn Alcohol Craving Scale and the Obsessive Compulsive Drinking Scale for Assessing Craving in a Clinical Sample. *Res. Soc. on Alcoholism* 30:161A.
107. Kramer DA, Champagne F, Copans S, Freeman W, **Mrazek DA** (2006), What does “Johnny has a chemical imbalance” really mean? *American Association of Child and Adolescent Psychiatry Proceedings*, pp. 94.
108. **Mrazek DA** (2006), The implementation of pharmacogenomic practice. *American Association of Child and Adolescent Psychiatry Proceedings*, pp. 95.
109. **Mrazek DA** (2006), Updates in pediatric psychosomatic medicine. *American Association of Child and Adolescent Psychiatry Proceedings*, pp. 109.
110. Kramer WE, Fisher PK, Walker D, O’Kane D, **Mrazek DA**, Black JL (2007), Analysis of Phase of Duplication in Cytochrome P450 2D6 Duplication Samples. *Biological Psychiatry* 61 (8S):400.
111. Kramer WE, Dukek BA, Walker D, Brufat JK, O’Kane DJ, **Mrazek DA**, Black JL (2007), Description of new cytochrome P450 2D6 (CYP2D6) alleles resulting from aberrant crossover between CYP2D6 and CYP2D7. *Biological Psychiatry* 61 (8S):408.
112. Karpyak VM, VanderWeg MW, Stevens SR, Cunningham JM, **Mrazek DA**, Black JL (2007) Alcohol withdrawal with seizures and DT: clinical and genomic correlates. *Biological Psychiatry* 61 (8S):436.

113. Faulkner LR, Winstead DK, Andrade NN, Brooks BA, **Mrazek DA**, Reiffler BV (2007) American Board of Psychiatry and Neurology Update: Certification and Maintenance of Certification in Psychiatry and its Subspecialties. *Issue Workshop 21, Proceedings of the American Psychiatric Association Annual Meeting*, pp. 249.
114. Schneekloth TD, Frye MA, Hall-Flavin DK, Karpyak VM, Drews MS, **Mrazek DA**. (2007) Alcoholism treatment follow-up: Development of a monitoring system to assess symptoms and outcome in a clinical cohort. *Alcohol Clin Exp Res 31(6 Suppl S):120A*.
115. Unal SS, Port JD, Wells LA, **Mrazek DA**, Felmlee JP, Marcus SM. (2007) The neurometabolic effects of long-term lithium treatment in adolescents with bipolar disorder: a phosphorus magnetic resonance spectroscopy study. *Bipolar Disorders 9(Suppl 1):106*.
116. Hall-Flavin D, **Mrazek DA**, Schneekloth TD, Karpyak VM, Loukianova LL, Frye MA. (2008) Current concepts in the treatment of addictive disorders: what is successful treatment in the era of translational medicine? *Oxford Round Table, March 9-14*.
117. Unal SS, Port JD, **Mrazek DA**, Felmlee JP, Marcus SM. (2007) Metabolic alterations detected with 3T CSF-corrected magnetic resonance spectroscopic imaging in medication-free patients with bipolar disorder. *Bipolar Disorders Jun; 9(Suppl 1):106*.
118. Hall-Flavin DK, Frye MA, Schneekloth TD, **Mrazek DA** (2008) Measurement of craving in bipolar patients admitted to an alcoholism treatment program. *Bipolar Disorders 10(Supplement 1):35*.
119. Black JL, Walker, DL, Kramer WE, O’Kane DJ, **Mrazek DA** (2008) Cytochrome P450 2D6: A model for mechanisms of genomic copy number variation. *Biol. Psych. 63:26*.
120. **Mrazek DA**, O’Kane DJ, Black, JL, Drews MS, Courson VL, Biernacka JM, Snyder KA, Rush AJ, Weinshilboum RM. (2008) An association of cytochrome P450 2C19 genotype and remission in patients treated with citalopram. *Biol. Psych. 63:251*.
121. **Mrazek DA**, Courson VL, Snyder KA, O’Kane DJ, Black JL. (2008) Associations between cytochrome P450 2D6 genotype and antidepressant medication tolerance. *Biol. Psych. 63:441*.
122. Karpyak VM, Kim JH, Biernacka JM, Wieben ED, **Mrazek, DA**, Black JL, Choi DS. (2008) Sequence variations in the human MPDZ gene in Caucasian alcoholic population. *Biol. Psych. 63:525*.
123. Karpyak, VM, Vander Weg MW, Biernacka JM, Stevens SR, Cunningham, JM, **Mrazek DA**, Black JL. Interaction effect of SLC6A4 and DRD2 Variations is associated with delirium tremens. XIV World Congress of Psychiatry, Prague, Czechoslovakia, September 20-25, 2008.

## **E. Other Publications**

1. **Mrazek DA** (1984), Science, politics, and ethics: Issues in the study of the sexual use of children. *Contemporary Psychology*, 30:37-38. (book review).
2. Strunk RC, **Mrazek DA** (1986), Reducing deaths caused by bronchial asthma. *Journal of the American Medical Association*, 255:1140. (letter).
3. **Mrazek DA** (1987), Psychobiological aspects of allergic disorders. *Psychosomatics*, 28:388-390. (book review).
4. **Mrazek DA** (1987), Crises of adolescence - teenage pregnancy: Impact on adolescent development. *Journal of the American Academy of Child and Adolescent Psychiatry*, 26:942-943. (book review).
5. **Mrazek DA** (1987), School-age pregnancy and parenthood: Biosocial dimensions. *Journal of the American Academy of Child and Adolescent Psychiatry*, 26:942-943. (book review).
6. **Mrazek DA** (1988), Preventing emotional problems in young children with asthma. *Breathing News and Views*, 4(2):1-4. (column).
7. **Mrazek DA**, Klinnert MD (1989), Asthma and serum levels of IgE. *New England Journal of Medicine*, 320:1696. (letter).
8. **Mrazek DA** (1990), Risk factors for early onset asthma. *Clinical Advances in the Treatment of Asthma*, 1:1.
9. Klinnert MD, Miller BD, **Mrazek DA** (1990), Asthma fatalities: Who's at risk? *Contemporary Pediatrics*, 7:81-98.
10. **Mrazek DA** (1991), Preface. In: Living with Asthma, ed. N. Altman, New York, Dell, ix-xi.
11. **Mrazek DA** (1994), Affect: Psychoanalytic perspectives. *Journal of the American Academy of Child and Adolescent Psychiatry*, 33:8:1212. (book review).
12. **Mrazek DA** (1994), Treatment interventions for prenatal, infant, and child populations. *New Research Frontiers in Behavioral Medicine: Proceedings of the National Conference*, eds. S. Blumenthal, K. Matthews, and S. Weiss, U.S. Government Printing Office, pp. 177-178.
13. **Mrazek DA** (1995), Your child's mental health: Finding help for emotional and behavioral problems. In: Raising Your Child in Washington, A Guide for the Growing Years, ed. R. Gottesman. Piccolo Press, 71-76.
14. **Mrazek DA** (1997), Making the move go as smoothly as possible. In: Health Matters.
15. **Mrazek DA** (1999), The new child and adolescent psychiatry. *AACAP News*, 30(4):135, 138.

16. **Mrazek DA** (1999), The genetics of autism. *AACAP News*, 30(5): 184, 189.
17. **Mrazek DA** (1999), The Jackson Lab experience. *AACAP News*, 30(6): 219, 221.
18. **Mrazek DA** (1999), Genetic medicine and genetic psychiatry. *AACAP News*, 31(1):16.
19. **Mrazek DA** (2000), MERGER interventions: psychotherapy meets the genome. *AACAP News*, 31(2):59.
20. **Mrazek DA** (2000), Genetics of bipolar. *AACAP News*, 31(3):112-113.
21. **Mrazek DA** (2000), Molecular genetics informing clinical practice. *AACAP News*, 31(4): 160-165.
22. **Mrazek DA** (2000), Will the truth set you free? *AACAP News*, 31(5):202.
23. **Mrazek DA** (2000), Translating the genome at the Mayo Clinic. *AACAP News*, 31(6):246-247.
24. **Mrazek DA** (2001), How many genes make up the human genome? *AACAP News*, 32(1).
25. **Mrazek DA** (2001), The challenge of the homeobox. *AACAP News*, 32(3):111-112.
26. **Mrazek DA** (2001), The phenotype muddle. *AACAP New*, 32(4):162-163.
27. **Mrazek DA** (2001), The X chromosome and the development of empathy. *AACAP News*, 32(5):214-215.
28. **Mrazek DA** (2001), Gene chip technology and psychiatric diagnosis. *AACAP News*, 32(6):272-273.
29. **Mrazek DA** (2001), A new look at internalizing disorders beginning in childhood, editorial overview in *Current Opinions in Pediatrics* 13:579.
30. **Mrazek DA** (2001), A crisis in child psychiatric service delivery: Why hasn't the piper been paid? *Mayo Clin Proc* 76(11):1078-1080.
31. **Mrazek DA** (2002), 2D6 polymorphisms and the treatment of depression. *AACAP News* 33(1):11-12.
32. **Mrazek DA** (2002), What can we learn from *A Beautiful Mind*? *AACAP News* 33(2):61-63.
33. **Mrazek DA** (2002), The 7R Allele of DRD4, *AACAP News* 33(3):220-221.
34. **Mrazek DA** (2002), Novel approaches designed to assess pathological behaviors, *Current Opinions in Pediatrics* 14(6):707. (editorial overview)
35. **Mrazek DA** (2002), Psychiatric Genomics 101, *AACAP News* 33(6):295.
36. **Mrazek DA** (2003), Learning about polymorphisms, *AACAP News* 34(1):19-20.

37. **Mrazek DA** (2003), New Test Explores Genes and Psychopharmacology, *AACAP News* 34(2):78-79.
38. **Mrazek DA** (2003), Genetic variation in the risk for developing schizophrenia. *AACAP News* 34(3):144-145.
39. **Mrazek DA** (2003), Real Genes Associated with the Risk for Schizophrenia, *AACAP News* 34(4):200-201.
40. **Mrazek DA** (2003), The Biology of Evil Thoughts, *AACAP News* 34(5):259 and 273.
41. **Mrazek DA** (2003), Recognizing Genomic Paradigm Shifts, *AACAP News* 34(6):336-337.
42. **Mrazek DA** (2003), The Assessment of the Child with an Organic Psychiatric Disorder: A Genetic Approach, *American Journal of Medical Genetics: Neuropsychiatric Genetics* (review).
43. **Mrazek DA** (2004), Genotyping to Guide Clinical Practice, *AACAP News* 35(1):20-21.
44. **Mrazek DA** (2004), The Unseen Genome, *AACAP News* 35(2):60-61.
45. **Mrazek DA** (2004), The pharmacogenomics of pain control, *AACAP News* 35(3):105-107.
46. **Mrazek DA** (2004), The adoption of pharmacogenomic testing, *AACAP News* 35(4):160-161.
47. **Mrazek DA** (2004), Better psychotropic medications, *AACAP News* 35(5):210-215.
48. **Mrazek DA** (2004), New psychiatric endophenotypes, *AACAP News* 35(6):284-289.
49. Kung S, **Mrazek DA** (2005), Psychiatric Emergency Department Visits on Full-Moon Nights, *Psychiatric Services* 56(2):221-222. (letter)
50. **Mrazek DA** (2005), Are You Learning Enough About Pharmacogenomics, *Develop Mentor* (online article submission)
51. **Mrazek DA** (2005), Psychiatry in the genomics era, *AACAP News* 36(1):12-21.
52. **Mrazek DA** (2005), The dopamine pathway, *AACAP News* 36(2):70-79.
53. **Mrazek DA** (2005), A Potentially Fatal Drug Interaction in Children Who Are 2D6 Ultra-Rapid Metabolizers. *AACAP News* 36(3):114-115.
54. **Mrazek DA** (2005), The First Objective Clues to the Causes of Mental Illness. *AACAP News* 36(4):165 and 171.
55. **Mrazek DA** (2005), Can we predict the response of patients to Olanzapine? *AACAP News* 36(5):216-223.

56. **Mrazek DA** (2005), The Ophelian Quartet, *AACAP News* 36(6):288-298.
57. Gibbs C, Fisher P, Hernandez, J., **Mrazek D**, O’Kane D, & Snyder K (2005), Cytochrome P450 enzyme genotyping: optimizing patient care through pharmacogenetics. *Communique*, 30(9): 1-9.
58. **Mrazek D** (2005), Pharmacogenomic screening for depressed children and adolescents. *Psychiatric Times*, XXII(9): 24-25.
59. **Mrazek DA**, Smoller JW, de Leon J, Ginsberg DL. (2006), Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. *CNS Spectrums* 11(3): 1-2.
60. **Mrazek DA** (2006), Clinical implications of hemizygoty of the COMT Gene, *AACAP News* 37(1):20-52.
61. **Mrazek DA** (2006), The Fluoxetine paradox, *AACAP News* 37(2):77-78.
62. **Mrazek DA** (2006), The Serotonin Transporter Gene: SLC6A4 Promoter Variation. *AACAP News* 37(3): 139-140.
63. **Mrazek DA** (2006), Variation in the serotonin 2A receptor is linked to antidepressant response. *AACAP News* 37(4):196-197.
64. **Mrazek DA** (2006), Pseudogenes: archeological remnants of our past. *AACAP News* 37(5):258-259.
65. **Mrazek DA** (2006), Thinking about genes: the NMDA receptor genes. *AACAP News* 37(6):324-325.
66. **Mrazek DA** (2007), When Genotyping Can Save the Life of an Infant. *AACAP News*, 38(3):120-121.
67. **Mrazek DA** (2007), Thinking about Genes: The Discovery of a New 2C19 Allele. *AACAP News*, 38(4):174-175.
68. **Mrazek DA** (2007), Thinking about Genes: How Many Deaths Will it Take? *AACAP News*, 38(5): 232-233.
69. **Mrazek DA** (2007), Thinking about Genes: Learning about 2C9. *AACAP News*, 38(6): 300-301.
70. **Mrazek DA** (2008), Thinking about Genes: A Life Decoded as a Prelude to “Decode Me”. *AACAP News*, 39(1):18-19.
71. **Mrazek DA** (2008), Thinking about Genes: Environmental Influences on the Expression of the CYP1A2 Gene. *AACAP News*, 39(3):112-113.

## **F. Selected Invited Lectures and Papers Presented at Scientific Meetings**

1. **Mrazek DA** (1976), An approach to teaching forensic child psychiatry. Presented at the American Association of Psychiatric Services for Children, San Francisco, California.
2. Robbins DE, Engstrom FW, **Mrazek DA**, Swift W (1977), Psychological characteristics of children of manic-depressive mothers. Presented at the Annual Meeting of the American Academy of Child Psychiatry, Dallas, Texas.
3. **Mrazek DA** (1980), A sequential analysis of mother-child interaction. Presented to the Developmental Psychobiology Research Group, Estes Park, Colorado.
4. **Mrazek DA**, Mrazek PB (1980), Family therapy as primary and secondary prevention for child abuse. Presented at the 10th Annual Child Abuse and Neglect Symposium, Keystone, Colorado.
5. **Mrazek DA** (1980), Developmental issues of chronic illness in asthmatic children. Presented to the Developmental Psychobiology Research Group, Denver, Colorado.
6. **Mrazek DA** (1980), Severe asthma in the preschool child: Impact on parent-child interaction. Presented at the Annual Meeting of the American Academy of Child Psychiatry, Chicago, Illinois.
7. Corwin D, **Mrazek DA** (1981), Sexual abuse of children: Training child psychiatrists to deal with the unspeakable. Presented at the Annual Meeting of the American Academy of Child Psychiatry, Dallas, Texas.
8. **Mrazek DA** (1981), The preschool asthmatic child: Clinical implications of family interactional patterns. Presented at the Annual Meeting of the American Academy of Child Psychiatry, Dallas, Texas.
9. **Mrazek DA** (1981), A developmental approach to the preschool asthmatic child. Presented at the Judge Baker Child Guidance Clinic, Harvard Medical School, Boston, Massachusetts.
10. **Mrazek DA** (1981), Parent-child interaction research in 3 - 6-year-old asthmatics: A progress report. Presented to the Developmental Psychobiology Research Group, Denver, Colorado.
11. Mrazek PB, **Mrazek DA** (1981), Treatment of the sexually abused child within the family. Presented to the Colorado Society of Child and Adolescent Psychiatry, Colorado Springs, Colorado.
12. **Mrazek DA** (1982), Asthma: Psychological aspects with children. Presented at the Boulder Psychiatric Institute, Boulder, Colorado.
13. **Mrazek DA** (1982), Multiple hospitalizations: What are the developmental consequences? Presented to the Developmental Psychobiology Research Group, Estes Park, Colorado. (Accepted for publication in Conference Proceedings).

14. **Mrazek DA**, Helfend L (1982), Severe psychopathology in asthmatic children. Presented at the Annual Meeting of the American Academy of Child Psychiatry, Washington, D. C.
15. **Mrazek DA**, Stolp R, Falco J, Coustry M, Pollard I (1982), Developing an early intervention program for young asthmatic children. Presented at the Pittsburgh First-Born Project, Pittsburgh, Pennsylvania.
16. Emde R, **Mrazek DA**, Wright M (1983), Nosology in early childhood: application of current research in relation to DSM 3. Presented at The Annual Meeting of the Colorado Child and Adolescent Psychiatric Society, Infant, Colorado.
17. **Mrazek DA** (1983) Child psychiatry clinical research training. Presented at the Children's Psychiatric Center, Cincinnati, Ohio.
18. **Mrazek DA** (1983), Emotional development of preschool asthmatic children. Presented at Psychiatric Grand Rounds at the University of Cincinnati, Cincinnati, Ohio.
19. **Mrazek DA** (1983), Hospital effects on early development. Presented to the Department of Pediatrics, Children's Hospital, Cincinnati, Ohio.
20. **Mrazek DA** (1983), Psychiatric essay award discussant. Presented at the Cincinnati Psychiatric Society, Cincinnati, Ohio.
21. **Mrazek DA**, Anderson I (1983), An observational methodology for analyzing the quality of mother-child interactions. Presented at the Annual Meeting of the American Academy of Child Psychiatry, San Francisco, California.
22. **Mrazek DA**, Anderson I, Klinnert M, Szeffler S, Strunk R C (1983), Behavioral effects of theophylline on preschool asthmatic children. Presented at the Annual Meeting of the American Academy of Child Psychiatry, San Francisco, California.
23. **Mrazek DA**, Harmon R, Glick A, Koocher G, Miller B, Silverstein R, Wolfson G (1983), Clinical interventions with dying children and their families. Presented at the Annual Meeting of the American Orthopsychiatry Association, Boston, Massachusetts.
24. **Mrazek DA**, Strunk R, Falco J, Stolp R, Coustry M (1983), Early intervention for chronically ill children. Presented at the Annual Meeting of the Association for the Care of Children's Health, Chicago, Illinois.
25. Miller BD, **Mrazek DA** (1984), Heart rate variability as a measure of physiologic temperament in newborns. Presented at the Annual Meeting of the American Academy of Child Psychiatry, Toronto, Ontario.
26. **Mrazek DA** (1984), Childhood asthma: Causes and consequences. Presented to the Developmental Psychobiology Research Group, Denver, Colorado.
27. **Mrazek DA** (1984), Mother-child interaction: A time-series approach to analysis of affect. Presented to the Developmental Psychobiology Research Group, Estes Park, Colorado.

28. **Mrazek DA**, Anderson I, Wolfson G, Strunk R (1984), Emotional sequelae of early onset severe asthma: Do children "grow out of it?" Presented at the Annual Meeting of the American Academy of Child Psychiatry, Toronto, Ontario.
29. **Mrazek DA**, Masterson J (1984), The children's global assessment scale (CGAS) in a pediatric setting: Consideration of reliability and validity. Presented at the Annual Meeting of the American Academy of Child Psychiatry, Toronto, Ontario.
30. **Mrazek DA**, Strunk RC (1984), Chronic asthma, children and death. Presented at the Keystone Summit 1984 on Allergy, Immunology, Pulmonology and ENT, Keystone, Colorado.
31. Strunk RC, **Mrazek DA** (1984), Factors associated with asthma death. Presented at the Denver Allergy Grand Rounds, Denver, Colorado.
32. Frank SM, Kaplan S, Miller B, **Mrazek DA**, Rubenstein B (1985), Depressive symptomatology in chronic illness. Presented at the Annual Meeting of the American Academy of Child Psychiatry, San Antonio, Texas.
33. Miller BD, Klinnert MD, **Mrazek DA** (1985), Refractoriness in asthmatic children to traditional pediatric care - medical noncompliance, misbehavior, or emotional disturbance? Presented at the Eighth World Congress of the International College of Psychosomatic Medicine, Chicago, Illinois.
34. **Mrazek DA** (1985), Genetic considerations in determining the risk of psychological sequela in severely asthmatic preschool children. Presented at the International College of Psychosomatic Medicine, Chicago, Illinois.
35. **Mrazek DA** (1985), Psychological and physiological predictors of asthmatic mortality. Presented at the University of Colorado School of Medicine Child Psychiatry Grand Rounds, Denver, Colorado.
36. **Mrazek DA** (1985), Psychological risk factors in early onset asthma. Presented to the Colorado Child and Adolescent Psychiatric Society, Denver, Colorado.
37. **Mrazek DA** (1985), Recent research examining psychological factors in childhood asthma. Presented to the Greater Phoenix Allergy Society, Phoenix, Arizona.
38. Strunk RC, **Mrazek DA** (1985), Clinical issues related to asthma death. Presented to the University of Colorado School of Medicine Pediatric Grand Rounds, Denver, Colorado.
39. **Mrazek DA**, Mrazek PJ, Klinnert MD (1986), The dyadic adjustment scale: Does it predict clinical assessments of marital satisfaction? Poster presented to the Developmental Psychobiology Research Group Retreat, Estes Park, Colorado.
40. **Mrazek DA** (1986), The need to be normal. Presented at the Association for the Care of Asthma meeting, Philadelphia, Pennsylvania.
41. **Mrazek DA** (1986), Children with asthma: At risk for developmental psychopathology. Presented at Rhode Island Hospital, Providence, Rhode Island.

42. **Mrazek DA** (1986), Primary care approaches to the emotional problems of asthmatic children. Faculty lectures sponsored by the Association for the Care of Asthma, Honolulu, Hawaii.
43. **Mrazek DA** (1986), Psychiatric considerations in pediatric asthma. Presented at Grand Rounds at The Royal Children's Hospital, Melbourne, Australia.
44. **Mrazek DA** (1986), Psychological factors associated with fatal asthmatic attacks. Presented at the Child Psychiatry Society of Victoria, Melbourne, Australia.
45. **Mrazek DA** (1986), Physical and sexual child abuse. Invited plenary address to the North Queensland Medical Conference, Townsville, Australia.
46. **Mrazek DA** (1986), Psychosomatic aspects of pediatric asthma. Invited lecture, University of Oslo, Oslo, Norway.
47. **Mrazek DA, Casey B** (1986), Clinical ratings of psychopathology in preschool children: Association with attachment ratings and scores on the Behavioral Screening Questionnaire. Presented to the MacArthur Foundation Summer Institute, Cape Cod, Massachusetts.
48. **Mrazek DA, Mrazek PJ, Klinnert M** (1986), The dyadic adjustment scale: Does it predict clinical assessments of marital satisfaction? Presented to the Developmental Psychobiology Research Group Retreat, Estes Park, Colorado.
49. **Mrazek DA** (1987), Severe asthma and psychopathology: What's the link? Invited lecture to the Department of Psychological Medicine, Hospital for Sick Children at Great Ormond Street, London, England.
50. **Mrazek DA** (1987), Do emotional factors contribute to the onset of asthma in young children? Lecture to the Child Psychiatry Medical Research Council Unit, Institute of Psychiatry, May, 1987, London, England.
51. **Mrazek DA** (1987), Why do some children with asthma develop psychiatric problems? Invited lecture at the University of Manchester School of Medicine, Manchester, England.
52. **Mrazek DA** (1987), Assessing psychological risk factors in chronically ill children. Invited lecture at the Free University of Berlin, Berlin, Germany.
53. **Mrazek DA** (1987), Psychiatric implications of severe childhood asthma. Psychiatry Grand Rounds, University of California, San Francisco, California.
54. **Mrazek DA** (1987), Child development effects of early maternal depression. Presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, D.C.
55. **Mrazek DA** (1987), Can stress affect the onset of asthma in children? Presented at Department of Psychiatry Grand Rounds, Cornell University, New York, New York.
56. **Mrazek DA** (1987), Is asthma a risk factor for emotional development? Presented at Child Psychiatry Grand Rounds, Cornell University, New York, New York.

57. **Mrazek DA**, Klinnert MD (1987), Progress on the Asthma Risk Project. Presented to the Developmental Psychobiology Research Group, Denver, Colorado.
58. **Mrazek DA**, Klinnert MD, Anderson IS (1987). Smoking in asthmatics. Poster presented at the Epidemiology Exchange, University of Colorado Health Sciences Center, Denver, Colorado.
59. **Mrazek DA**, Brower A, Bzdek S, Anderson I, Jones J, Klinnert M (1987), Respiratory viral infections in the first year of life. Presented at the University of Colorado Pediatric Clinical Research Center 25th Anniversary Meeting, Denver, Colorado.
60. **Mrazek DA** (1988), Psychological factors affecting the course and expression of asthma. Presented at Department of Psychiatry Grand Rounds, University of Wisconsin, Madison, Wisconsin.
61. **Mrazek DA** (1988), Emotional stressors and pediatric illness: Untangling the cause and effect dilemma. Visiting Professor Colloquia, University of Pennsylvania, Philadelphia, Pennsylvania.
62. **Mrazek DA**, Klinnert M (1988), Preventive intervention in infants at risk for atopic illness. Presented at the Third Biennial Conference of the International Association for Infant Mental Health, Providence, Rhode Island.
63. **Mrazek DA**, Klinnert MD, Brower A, Anderson I (1988), Early viral illness and wheezing. Presented at the University of Colorado Pediatric Clinical Research Center Annual Meeting, Denver, Colorado.
64. **Mrazek DA**, Klinnert M, Mrazek P, Macey T, Anderson I (1989), Can early psychopathology be predicted based on perinatal clinical observations? Presented at the First Annual Meeting of the Society for Research in Child and Adolescent Psychopathology, Miami, Florida.
65. **Mrazek DA** (1989), Immunology, allergy, and stress: Risk factors for onset of asthma. Presented to the Behavioral Immunology Research Group, Denver, Colorado.
66. **Mrazek DA** (1989), Emotional stressors associated with early asthma onset. Presented to the MacArthur Foundation Scientific Advisory Committee, Denver, Colorado.
67. **Mrazek DA**, Klinnert MD, Anderson I, Russell C, Mrazek P (1990), Protective factors in resilient two-year-olds. Presented at the Second Annual Meeting of the Society for Research in Child and Adolescent Psychopathology, Irvine, California.
68. Fulker DW, Phillips K, DeFries JD, Harmon R, **Mrazek, DA** (1990), Genetic etiology of individual differences in temperament and problem behavior during the transition from infancy to early childhood. Presented at the Sixth Biennial Developmental Psychobiology Research Group Retreat, Estes Park, Colorado.
69. Klinnert MD, **Mrazek DA**, Mrazek P (1990), The clinical assessment of coping and environmental stressors. Presented at the Rosenberry Conference, Children's Hospital, Denver, Colorado.

70. **Mrazek DA**, Klinnert MD, Russell C (1990), Early asthma onset: Is breastfeeding protective? Presented at the Sixth Biennial Developmental Psychobiology Research Group Retreat, Estes Park, Colorado.
71. Rubin BC, Klinnert MD, Rosenberg DM, Brower A, Landow C, Young K, McCormick D, **Mrazek DA** (1990), The role of maternal sensitivity and affect regulation in the development of attachment. Presented at the Sixth Biennial Developmental Psychobiology Research Group Retreat, Estes Park, Colorado.
72. Rubin BC, Klinnert MD, **Mrazek DA** (1990), The relationship of attachment to the development of early childhood psychopathology. Presented at the Sixth Biennial Developmental Psychobiology Research Group Retreat, Estes Park, Colorado.
73. **Mrazek DA** (1990), Psychological factors and asthma management. Presented at the Annual Meeting of the Academy of Allergy and Immunology, Baltimore, Maryland.
74. **Mrazek DA**, Klinnert M, Mrazek P (1990), An interview-based method for assessing stress and coping. Presented at the Rosenberry Conference, Denver, Colorado.
75. **Mrazek DA** (1991), Influencing gene expression through environmental manipulation: A psychosomatic model. Presented at Psychiatry Grand Rounds, University of Colorado School of Medicine, Denver, Colorado.
76. **Mrazek DA** (1991), Family assessment. Presented at the Scientific Meeting of the Committee on Chronic Illness of the American Academy of Child and Adolescent Psychiatry, Denver, Colorado.
77. **Mrazek DA** (1991), Roerig Lecture - Emotional development of children with illness in dysfunctional families. Presented at the University of California at Davis, California.
78. **Mrazek DA** (1991), Reducing the risk of asthma: Primary prevention. Presented at the University of California at Davis, California.
79. **Mrazek DA** (1991), A new intervention project for children at risk for the development of asthma. Presented at Psychiatry Grand Rounds, University of California at Davis, California.
80. **Mrazek DA** (1991), Parent-child attachment in children at risk for asthma. Presented at Scientific Annual Meeting of the Developmental Psychobiology Research Group, Denver, Colorado.
81. **Mrazek DA** (1991), Chronically ill children: Developmental issues. Presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, California.
82. **Mrazek DA** (1991), Psychiatric aspects of asthma. Presented at Psychiatric Aspects of Pediatric Practice, Fairfax Hospital, Falls Church, Virginia.
83. Klinnert MD, **Mrazek DA**, McCormick D, Young K, Dunhill C (1992), Viral illness in children genetically at risk for asthma. Presented at University of Colorado Pediatric Research Center Meeting, Denver, Colorado.

84. Rubin BC, **Mrazek DA**, Klinnert MD, Young K, McCormick D (1992), Attachment and the development of early psychopathology. Seventh Biennial Developmental Psychobiology Research Group Retreat, Estes Park, Colorado.
85. **Mrazek DA** (1992), Can the onset of asthma be delayed in vulnerable children? Presented at the 41st Ruth Gray Lecture, The Evanston Hospital, Evanston, Illinois.
86. **Mrazek DA** (1992), The asthmatic mother and son. Presented at Pediatric Grand Rounds, University of Chicago, Chicago, Illinois.
87. **Mrazek DA** (1992), Psychiatric predictions of asthma. Presented at Psychiatry Grand Rounds, Walter Reed Army Medical Center, Washington, D.C.
88. **Mrazek DA** (1992), Borderline of psychiatry and neurology: Treatment of childhood behavioral disorders. Presented at Pediatric Neurology Update 1992, Children's National Medical Center, Washington, D.C.
89. **Mrazek DA** (1992), Assessment of preschool children. Presented at American Psychiatric Association 145th Annual Meeting, Washington, D.C.
90. **Mrazek DA** (1992), Discovery and challenge: reflections on childhood resilience. Presented at The 1992 National Symposium on Child Victimization, Washington, D.C.
91. **Mrazek DA** (1993), Behavioral genetic therapy. Presented as the Laufer Memorial Lecture, Brown University, Providence, Rhode Island.
92. Garrison W **Mrazek DA** (1993), A guide to your child's behavior. Presented at the 78<sup>th</sup> Annual Fall Convention of the Maryland Congress of Parents & Teachers, Inc., Baltimore, Maryland.
93. **Mrazek DA** (1994), Psychological factors in asthma. Presented at Eastern/Southwestern Allergy Conference, Palm Beach, Florida.
94. **Mrazek DA** (1995), Incorporating research into clinical care: database management. Presented at the Annual Meeting of the Society of Professors of Child and Adolescent Psychiatry, Key West, Florida.
95. **Mrazek DA** (1996), Psychophysiological asthmatic research, American Society of Psychophysiology, Albuquerque, New Mexico.
96. **Mrazek DA** (1996), Environmental influences on the expression of attention deficit disorder. Tenth Annual Scientific Symposium, Children's Research Institute, Washington, D.C.
97. **Mrazek DA** (1997), Child psychiatric approaches designed to influence gene expression. Presented at Johns Hopkins University Child Psychiatry Grand Rounds, Baltimore, Maryland.
98. **Mrazek DA** (1997), Can asthma onset be delayed in young at-risk children? Presented at Montreal Children's Hospital Grand Rounds, Montreal, Quebec, Canada.

99. **Mrazek DA** (1997), L'influence de l'environnement sur l'expression genetique: Des considerations sur le developpement premature. Presented at the Hospitale Ste. Justine, Montreal, Quebec, Canada.
100. **Mrazek DA** (1998), Clinical psychopharmacology. Presented at the American College of Child and Adolescent Psychiatrists' Annual Meeting, San Juan, Puerto Rico.
101. **Mrazek DA** (1998), Genetic variability in the metabolism of serotonin reuptake inhibitor, Plenary Speaker at the Third National Conference on Child and Adolescent Mental Health, Sydney, Australia.
102. **Mrazek DA** (1998), Biological paradigms that inform the design of preventive interventions. Presented at Society for Prevention Research. Park City, Utah.
103. **Mrazek DA** (1998), New opportunities in child psychiatry research. Presented at Child and Adolescent Psychiatry Grand Rounds, Children's National Medical Center, Washington, D.C.
104. **Mrazek DA** (1999), Update of child psychiatric genetics. Presented at Society of Professors of Child and Adolescent Psychiatry, Santa Fe, New Mexico.
105. **Mrazek DA** (1999), Early interventions for children at risk for bipolar disorder. Presented at Psychiatry Grand Rounds, Mayo Clinic, Rochester, Minnesota.
106. **Mrazek DA** (1999), Genetic insights to childhood psychopathology. Minnesota Society of Child and Adolescent Psychiatry, Rochester, Minnesota.
107. **Mrazek DA** (1999), Genetics of aging. Geriatric Care Conference, Fairfax, Virginia.
108. **Mrazek DA** (1999), The new genetic paradigm: Applications for preventive research. Presented at Society for Prevention Research. New Orleans, Louisiana.
109. **Mrazek DA** (1999), Early interventions for children at risk for bipolar disorder. Presented at Psychiatry Grand Rounds, The George Washington University, Washington, D.C.
110. **Mrazek DA** (1999), The genome project: Implications for psychiatry. Presented at Grand Rounds, Cleveland Clinic Foundation, Cleveland, Ohio.
111. **Mrazek DA** (1999), Prevention strategies for genetically at risk children. Presented at the Johns Hopkins University School of Public Health and Hygiene, Baltimore, Maryland.
112. **Mrazek DA** (2000), Genetics of bipolar disorder: Past insights, current research and future implications. Presented at Psychiatry Grand Rounds, Mayo Clinic, Rochester, Minnesota.
113. **Mrazek DA** (2000) Is it possible to prevent bipolar disorder? Presented at Washington Council of Child and Adolescent Psychiatry Tenth Annual Symposium: Children of Affectively Ill Parents: Treatment and Prevention, Washington, D.C.

114. **Mrazek DA** (2000) The genetic blueprint for early emotional development. Presented at Washington Psychiatric Society: Brain Research and the Mapping of the Human Genome: Applications to Primary Care and Psychiatric Medicine, Washington, D.C.
115. **Mrazek DA** (2000), Bipolar spectrum disorder: Genetic hypotheses. Presented at the American Psychiatric Association Annual Meeting, Chicago, Illinois.
116. **Mrazek, DA** (2000), The Genetics of Bipolar Disorder. Presented at The Children's National Medical Center, Washington, D.C.
117. **Mrazek, DA** (2000), Early selective and indicated prevention strategies. Presented as an "Honors" plenary at the American Psychiatry Annual Meeting, New York, New York.
118. **Mrazek, DA** (2000), Diagnostic applications genomic screening in psychiatry. Presented at the International Meeting of the Mayo Alumni, Atlanta, Georgia.
119. **Mrazek, DA** (2001), Understanding the genetics of bipolar disorder. Presented at the Mayo Genetics Society, Rochester, Minnesota.
120. **Mrazek, DA** (2001), Juvenile onset bipolar disorder. Presented at Psychiatry Grand Rounds, University of Minnesota, Minneapolis, Minnesota.
121. **Mrazek, DA** (2001), Genomic applications to enhance diagnosis and treatment. Presented at the International Meeting of the Mayo Alumni, Rochester, Minnesota.
122. **Mrazek, DA** (2001), Molecular child and adolescent psychiatry. Presented at the Western Slope Psychiatric Symposium, Ouray, Colorado.
123. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Hankin CH, Pankratz VS, **Mrazek DA**, Jacobsen (2002), Gender Differences in Psychoactive Medication Treatment for ADHD: Results from a population-based study. Presented at the International Society for Pharmacoeconomics and Outcomes Research 6<sup>th</sup> Annual European Congress, Barcelona, Spain.
124. **Mrazek, DA** (2002), Interventions Designed to Change Parenting Behavior. 49<sup>th</sup> Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, California.
125. **Mrazek, DA** (2002), Pharmacogenomic Screening for Atypical SSRI Metabolism. 49<sup>th</sup> Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, California.
126. **Mrazek DA** (2003), Pharmacogenetics in Child and Adolescent Psychiatry. Presented at the Washington State Council of Child and Adolescent Psychiatry Fall Meeting, Seattle, Washington.
127. **Mrazek DA** (2004), Psychiatric Pharmacogenomics. Presented at the American College of Psychiatrists "Clinical Psychiatry in the Genetic Revolution" Meeting, Miami Beach, Florida.

128. **Mrazek DA**, Snyder KA, Black JL, O’Kane DJ (2004), Clinical Application of Pharmacogenomic Testing in Psychiatric Practice. Presented at the Royal College of Psychiatry presentations, Harrogate, U.K.
129. **Mrazek DA** (2004), Basic Principles of Molecular Genetics for Psychiatrists; Pharmacogenomics of Antidepressant Medications. Presented at the Fifth Annual Psychiatric Lecture Series, Sioux Falls, SD.
130. **Mrazek DA** (2004) Psychiatric Pharmacogenomics, Grand Rounds Presentation, Institute of Living, Hartford, CT
131. **Mrazek DA** (2005) Pharmacogenomics of Psychotropic Medication, University of Southern California, Los Angeles, CA
132. **Mrazek DA** (2005) Psychiatric Clinical Genotyping, Oschner Clinic, New Orleans, LA
133. **Mrazek DA** (2005) The Era of Personalized Medicine, The Usdin Memorial Lecture, New Orleans, LA
134. **Mrazek, DA** (2005) Pharmacogenomic Applications within Cultural Context, Presented at the XIII World Congress of Psychiatry in Cairo, Egypt
135. **Mrazek DA** (2005) Translational Genomic Clinical Research Initiatives, Presented at the XIII World Congress of Psychiatry in Cairo, Egypt
136. **Mrazek DA** (2005) Issues of Pharmacogenomics in Children and Adolescents, Presented at the Columbia University Graduate Center, New York, NY
137. **Mrazek DA** (2005) Controversies in the Diagnosis and Treatment of Pediatric Mood Disorder, presented at the Society for Developmental and Behavioral Pediatrics in San Diego, CA
138. **Mrazek DA** (2005) How Eiger Formulations Inform our Understanding of Pediatric Illness, The Simon Wile Award, Lecture presented at the American Academy of Child and Adolescent Psychiatry in Toronto, Ontario, Canada
139. **Mrazek DA** (2006) Pediatric Bipolar Disorder: Diagnostic and Treatment Challenges, Presented at Grand Rounds, Mayo Clinic Department of Pediatrics, Rochester, MN
140. **Mrazek DA** (2006) The Pharmacogenomics of Antidepressants Presented at the University of Arkansas, Little Rock, AK
141. **Mrazek DA** (2006) Pharmacogenomic applications in clinical practice presented at the Roche Psychiatry Scientific Advisory Board Meeting in Toronto, Ontario, Canada
142. **Mrazek, DA** (2006) Environmental Influences on Gene Expression and Regulation: EIGER Formulations. University of Colorado School of Medicine, Denver CO.
143. **Mrazek, DA** (2006) The Development of Asthma: Environmental Influences on Gene Expression and Regulation. International Society for the Advancement of Respiratory Psychophysiology, Newport, RI.

144. **Mrazek, DA** (2006) Pharmacogenomia en Psiquitria. Universidad Nacional de San Agustin, Arequipa, Peru.
145. **Mrazek, DA** (2006) Factores Geneticos y Psicologicos Asociados con el Asma Bronquial, Universidad Nacional de San Agustin, Arequipa, Peru.
146. **Mrazek DA** (2006) Psychiatric pharmacogenomics to be presented as a plenary lecture at the World Psychiatry Association in Lima, Peru.
147. **Mrazek DA** (2006) Pharmacogenomic Implications for the Use of Antidepressant Medications. Medical University of South Carolina, Charleston, SC.
148. **Mrazek DA** (2007) Psychiatric Pharmacogenomics. University of Hawaii, Honolulu, Hawaii.
149. **Mrazek DA** (2007) Clinical Case Presentations. Psychiatry Pharmacogenomics Course, Poipu Beach, Kauai, Hawaii.
150. **Mrazek DA** (2007) Announcement and Overview. Psychiatry Pharmacogenomics Course, Poipu Beach, Kauai, Hawaii.
151. **Mrazek DA** (2007) Influence of Target Genes on Drug Response. Psychiatry Pharmacogenomics Course, Poipu Beach, Kauai, Hawaii.
152. **Mrazek DA** (2007) P450 Microarray to Assess Atypical Drug Responses. Psychiatric Genomics: Applications for Clinical Practice. Rochester, MN
153. **Mrazek DA** (2007) Introduction to Psychiatric Genomics. Psychiatric Genomics: Applications for Clinical Practice. Rochester, MN.
154. **Mrazek DA** (2007) Future Implication for Genetic Testing in Psychiatry. Psychiatric Genomics: Applications for Clinical Practice. Rochester, MN.
155. **Mrazek DA** (2007) Eiger Formulations and Environmental Influence of Gene Expression and Regulation. University of Hawaii, Honolulu, Hawaii.
156. **Mrazek DA** (2007) Applications of Psychogenomic Testing in Clinical Practice. Mayo Clinic Scottsdale.
157. **Mrazek DA** (2007) Understanding Changing Prescribing Habits and How They May Impact R&D. R&D Leader's Forum, Philadelphia, PA.
158. **Mrazek DA** (2007) Imaging Genetics. Pharmacogenetic and Pharmacogenomic Keys. Improving Patient Outcomes through Biological Psychiatry: Discovery, Diagnosis and Treatment. Society of Biological Psychiatry. San Diego, CA.
159. **Mrazek DA** (2007) Progress in pharmacogenomics. Detection of Genetic Vulnerability. Improving Patient Outcomes through Biological Psychiatry: Discovery, Diagnosis and Treatment. Society of Biological Psychiatry. San Diego, CA.

160. **Mrazek DA** (2007) Recent Findings from Star\*D. Pharmacogenomic Genes. Improving Patient Outcomes through Biological Psychiatry: Discovery, Diagnosis and Treatment. Society of Biological Psychiatry. San Diego, CA.
161. **Mrazek DA** (2007) Pharmacogenomics and how it relates to comprehensive diagnostic evaluation and treatment. Association of Psychologists in Academic Health Centers 3<sup>rd</sup> National Conference, Minneapolis, MN.
162. **Mrazek DA** (2007) An Introduction to Psychiatric Pharmacogenomics. University of South Dakota, Sanford School of Medicine, Sioux Falls, SD.
163. **Mrazek DA** (2007) Using Pharmacogenomic testing to improve clinical outcomes today and in the future. University of South Dakota, Sanford School of Medicine, Sioux Falls, SD.
164. **Mrazek DA** (2007) Psychiatric Pharmacogenomics. Second Annual Dartmouth Pharmacogenomics Symposium. Applications of Pharmacogenomics in Clinical Practice: Present and Future. Dartmouth-Hitchcock Medical Center. Lebanon, New Hampshire.
165. **Mrazek DA** (2007) Psychiatric Pharmacogenomics. Depression Center Colloquium Series, University of Michigan Depression Center, Ann Arbor, MI.
166. Hall-Flavin D, Schneekloth TD, Karpyak VM, Loukianova LL, Biernacka J, Courson VL, **Mrazek DA**, Frye MA. (2008) Measurement of Craving and Its Relationship to Gender in Bipolar Patients Admitted to an Alcoholism Treatment Program. *(Poster) International Society of Bipolar Disorder Meeting, New Delhi and Agra, January 27-30, 2008.*
167. **Mrazek DA** (2008) New Insights into the clinical Significance of the Cytochrome P450 1A2 Gene. University of Hawaii, Honolulu, HI.
168. **Mrazek DA** (2008) Drug Metabolizing Enzyme Genes. Psychiatric Pharmacogenomics Course, March 2-4, 2008, Kauai, Hawaii.
169. **Mrazek DA** (2008) The Influence of Target Genes on Drug Response. Psychiatric Pharmacogenomics Course, March 2-4, 2008, Kauai, Hawaii.
170. **Mrazek DA** (2008) Future Applications and Implications of Clinical Genotyping. Psychiatric Pharmacogenomics Course, March 2-4, 2008, Kauai, Hawaii.
171. **Mrazek DA** (2008) Psychiatric Pharmacogenomics for the Clinician. Psychiatric Update. University of Wisconsin School of Medicine & Public Health and the Madison Institute of Medicine, Inc. Madison, WI.
172. **Mrazek DA** (2008) Biological Psychiatry: Past, Present and Future. Michigan Psychiatric Society Spring Scientific Meeting. Dearborn, MI.
173. **Mrazek DA** (2008) Psychiatric pharmacogenomics: Past Experiences and Future. Wisconsin Council of Child Psychiatry Annual Meeting. Milwaukee, WI

174. Schneekloth TD, Hall-Flavin DK, Loukianova LL, Karpyak VM, Frye MA, **Mrazek DA**. (2008) A New Minnesota Model: Mayo Clinic residential treatment. ASAM's 39<sup>th</sup> Annual Medical Scientific Conference, Toronto, Ontario, Canada.
175. **Mrazek DA** (2008) Psychiatric Pharmacogenomics. Kansas Medical Education Foundation. Topeka, KS.
176. **Mrazek DA** (2008) Pharmacogenomics of Antidepressants. Psychiatric Pharmacogenomics, Santiago, Chile.
177. **Mrazek DA** (2008) Future Applications and Implications of Clinical Genotyping. Psychiatric Pharmacogenomics, Santiago, Chile.
178. **Mrazek DA** (2008) A Pharmacogenomic Algorithm for Antidepressant Medication Selection and Dosing. Royal College of Psychiatrists Mtg. in London.
179. **Mrazek DA** (2008) Identification of the CYP2C19 Gene \*17 Allele in a Large Clinical Trial of Citalopram. XIV World Congress of Psychiatry, Prague.
180. **Mrazek DA** (2008) Clinical Psychiatric Pharmacogenomics: The Mayo Clinic Experience: Applications for the Management of Antidepressant Medication. XIV World Congress of Psychiatry, Prague.
181. **Mrazek DA** (2008) Clinical Psychiatric Pharmacogenomics: The Mayo Clinic Experience. XIV World Congress of Psychiatry, Prague.